2017/<u>19</u> PbR Excluded Drugs: proposed GMMMG Advisory Position [Appendix 3]

Date of this document:	Commissioner	Further notes	Note: many	Group: A group	Drugs in blue cells are	Highlighted cells	Highlighted cells	
April 2018. Updated in	category:	available at foot of	BNF	includes all drugs in	new additions for 2017/19.	are amendments	in this colour are	
line with Annex A of	C= CCG	spreadsheet	Categories	that group	Probable commissioner	made to 2016/17	amendments	
National tariff payment	N= NHS England	N.B. for NHSE-	inserted using	regardless of	indicated	version	made to 2017/19	
system 2017/19 issued		commissioned drugs,	NDO on NHSE	specific drugs listed.			version for 2018	
22.12.16 (no changes to	NHSE but not on	oonoun nino E		Individual - This is				
	V13 s/sheet			for the specific listed				
compared with V1.0			NHSE s/sheet	drug only				
which was approved by		position.	says "none" or					
GMMMG on 17th			"n/a"					For forthcoming new drugs, an
November 2016 and								expected time of availability is
with reference to NHSE								presented when stated by SPS
V13 spreadsheet dated								but this may change in the
<mark>23/03/18.)</mark>								future.

No.	Drug Name (some brand names added for clarity in italics)	Commissioner Category	PBR Category	BNF category (legacy)	Group	Indication	Prior Approval Category	Commissioning Policy Type	Commissioning Policy Link	Comments
	nancs)		AIDS/HIV			HIV in combination with				
1	Abacavir	Ν	antiretrovirals	5.3.1	Group	other anti-retroviral drugs				
	Abacavir with dolutegravir and lamivudine	Ň	AIDS/HIV	0.0.1		HIV in combination with				
2	Triumeg	Ν	antiretrovirals	5.3.1	Group	other anti-retroviral drugs				included to match NHSE list
3	Abacavir with lamivudine	Ν	AIDS/HIV antiretrovirals	5.3.1	Group	HIV in combination with other anti-retroviral drugs				included to match NHSE list
4	Abaloparatide	Ν	Drugs affecting bone metabolism	6.6.2	Individual	Male and juvenile osteoporosis				
			Drugs affecting bone			Postmenopausal	Individual			
5	Abaloparatide	С	metabolism	6.6.2	Individual	osteoporosis	Funding			s/c injection; not in PO
						Juvenille Idiopathic			ubgroups/sbgrp-hcdsg/Child- to-adult-services-statement-	For children transitioning to adult services and becoming a CCG commissioning responsibility, category is monitored when in line with the referenced GMMMG
6	Abatacept	N	Cytokine modulators	10.1.3	Group	Rheumatoid Arthritis			amended-post-meeting.pdf	guidance.
7	Abatacept	Ν	Cytokine modulators	10.1.3	Group	Paediatric indications (where adult TA available)		As per adult TA's (TA195, TA280)		
8	Abatacept	С	Cvtokine modulators	10.1.3	Group	Rheumatoid Arthritis, after failure of conventional DMARDs	Monitored	NICE TA375 / GM Harmonised biologics pathway	0Pathway%2022%20april_2	
0		C	Cvtokine modulators	10.1.3	Group	Rheumatoid Arthritis, after failure of TNF inhibitor, if rituximab contra-indicated		NICE TA195	http://guidance.nice.org.uk/T A195	
10	Abatacept Actoxumab + Beziotoxumab	C	Cytokine modulators		Group	Clostridium difficile infection -prevention of recurrence after 2nd+ episode	Individual funding			New 31.10.16 but SPS says development discontinued (actoxumab ineffectve, development restricted to bezlotoxumab)
11	Abiraterone	N	Hormone antagonists	8342	C. Cap	Cancer			l	included to match NHSE list

12	Adalimumab	Ν	Cytokine modulators	10.1.3	Group	Hidradenitis Suppurativa				
	/ launnan ab		e y tertaine inte dulatere		Cicup					For children transitioning to adult
										services and becoming a CCG
									http://gmmmg.nhs.uk/docs/s	commissioning responsibility,
									ubgroups/sbgrp-hcdsg/Child-	category is monitored when in
									to-adult-services-statement-	line with the referenced GMMMG
13	Adalimumab	N	Cytokine modulators	10.1.3	Group	Juvenille Arthritis			amended-post-meeting.pdf	guidance.
14	Adalimumab	N	Cytokine modulators	10.1.3	Group	Uveitis [paediatric]				
15	Adalimumab	N	Cytokine modulators	10.1.3	Group	Uveitis [adult]				
									http://guidance.nice.org.uk/T	
									A383	
								NICE TA383 / GM		
								Harmonised	http://gmmmg.nhs.uk/docs/g	
								Pathway for	uidance/GMMMG%20AS%2	
					-			biologics in AS	0PsA%20pathway%20v4%2	
16	Adalimumab	С	Cytokine modulators	10.1.3	Group	Ankylosing spondylitis	Monitored	and PsA.	0FINAL.pdf	
									http://guidance.nice.org.uk/T	
17	Adalimumab	С	Cytokine modulators	13.5.3	Group	Psoriasis (plaque)	Monitored	NICE TA146	A146	
									http://guidance.nice.org.uk/T A199	
								NICE TA199 / GM	A 199	
								Harmonised	http://googo.go.go.go.go.go.go.go.go.go.go.go.g	
									http://gmmmg.nhs.uk/docs/g uidance/GMMMG%20AS%2	
								Pathway for biologics in AS	0PsA%20pathway%20v4%2	
18	Adalimumab	С	Cytokine modulators	10.1.3	Group	Psoriatic Arthritis	Monitored	and PsA.	0FINAL.pdf	
10	Adaiimumab	C	Cytokine modulators	10.1.5	Group	PSOHAlic Arthitis	womitored	anu FSA.	http://gmmmg.nhs.uk/docs/g	
						Psoriasis (plaque) -			uidance/GMMMG-Biologics-	
						sequential use of biologic			pathway-for-psoriasis-v2-	reference to psoriasis pathway
19	Adalimumab	С	Cytokine modulators	13.5.3	Group	agents	Monitored	GMMMG	0.pdf	updated
10	/ daimanab	0	Cytokine modulators	10.0.0	Group	agents	Worldored		http://www.nice.org.uk/guida	upualed
									nce/ta375	
						Rheumatoid Arthritis, after		NICE TA375 / GM	http://gmmmg.nhs.uk/docs/g	
						failure of conventional		Harmonised	uidance/GMMMG-RA-	
20	Adalimumab	С	Cytokine modulators	10.1.3	Group	DMARDs	Monitored	biologics pathway		
			ĺ.		1 .	Rheumatoid Arthritis, after		· · · · ·	http://guidance.nice.org.uk/T	
						failure of TNF inhibitor, if			A195	
						rituximab contra-indicated,				
						or as monotherapy if			http://gmmmg.nhs.uk/docs/g	
						rituximab and		NICE TA195 / GM	uidance/GMMMG%20RA%2	
						methotrexate contra-		Harmonised	0Pathway%2022%20april_2	
21	Adalimumab	С	Cytokine modulators	10.1.3	Group	indicated	Monitored	biologics pathway		
						Crohn's Disease,			http://guidance.nice.org.uk/T	
22	Adalimumab	С	Cytokine modulators	1.5.3	Group	gastroenterology	Monitored	NICE TA187	<u>A187</u>	
		-				Ulcerative colitis,			http://www.nice.org.uk/guida	
23	Adalimumab	С	Cytokine modulators	1.5.3	Group	gastroenterology	Monitored	NICE TA329	nce/ta329	
24	Adalimumab	С	Cytokine modulators	10.1.3	Group	All other adult indications	Individual funding			Free dia a fan a a a l' d'
								TA 455		Funding for paediatric
								TA 455 or as per		indications not being treated at
						De a dia tria in 11 - 11		adult TA's		an NHSE-commissioned
25	Adaliasumah	N	Outokino modulot	10.1.2	Crown	Paediatric indications		(TA103, TA375,		Specialist Centre may also fall to CCGs
25	Adalimumab	N	Cytokine modulators	10.1.3	Group	(where adult TA available)		TA143, TA199)		Added to match NHSE s/sheet
26	Adalimumab	N	Cytokine modulators	10.1.3	Group	BehÇet's Syndrome				Added to match NHSE S/Sheet
			Viral Hepatitis (B&C) & respiratory Syncytial							
27	Adefovir	Ν	Virus	5.3.3	Group	Hepatits B				
21		IN	VIIUS	0.0.0	Joup		+		1	Approved in the EU and UK for
						Erythropoietic proto-				prophylactic treatment in adult
28	Afamelanotide	С	Skin Conditions	13.1	Individual	porphyria (EPP)	Individual funding			patients with EPP.
20	, traincianotide	0	Citin Conditions	10.1	mannaudi		In a mouth a funding	1	1	

			Protein kinase							
29	Afatinib	Ν	inhibitors	8.1.5	Individual					
30	Aflibercept	Ν	Cancer exclusion	8.1		Cancer				Added to match NHSE s/sheet
			Subfoveal choroidal		la di data l	Neovascular (wet) age- related macular	Ma wita wa d		http://guidance.nice.org.uk/T	
31	Aflibercept	С	neovascularisation	11.8.2	Individual	degeneration (AMD)	Monitored	NICE TA294	<u>A294</u>	
32	Aflibercept	С	Subfoveal choroidal neovascularisation	11.8.2	Individual	Visual impairment caused by macular oedema secondary to central retinal vein occlusion	Monitored	NICE TA305	http://www.nice.org.uk/guida nce/TA305	
			Subfoveal choroidal			Visual impairment caused by macular oedema secondary to branch			https://www.nice.org.uk/guid	New entry for positive NICE TA
33	Aflibercept	С	neovascularisation	11.8.2	Individual	retinal vein occlusion	Monitored	NICE TA 409	ance/ta409	for this indication.
			Subfoveal choroidal						http://www.nice.org.uk/guida	
34	Aflibercept	С	neovascularisation	11.8.2	Individual		Monitored	NICE TA346	nce/ta346	
35	Aflibercept	С	Subfoveal choroidal neovascularisation	11.8.3	Individual	Myopic choroidal neovascularisation	Monitored	NICE TA486	https://www.nice.org.uk/guid ance/ta486	New entry for positive NICE TA for this indication.
55	Ambercept	U	Lysosomal Storage	11.0.3		neovascularisation	MUTILUTED	NICE TA400	anut/la400	
36	Agalsidase alfa	Ν		9.8.1	Group	Fabry's disease				
			Lysosomal Storage		_					
37	Agalsidase beta	N	Disorder drugs	9.8.1	Group	Fabry's disease				
38	Aganirsen	N*	Subfoveal choroidal neovascularisation	11.8.2	Individual	Corneal neovascularisation associated with keratoplasty rejection				2018 NHSE commissions keratoplasty [PSS No.12]
30	Aganiisen	IN	neovascularisation	11.0.2	Individual	keralopiasty rejection				Tenofovir alafenamide is a pro-
20	Al-forentide	N	AIDS/HIV		0	1107				drug of tenofovir with the aim of improving renal and bone safety should really be with tenofovir
39	Alafenamide	N	antiretrovirals		Group	HIV				which is where NHSE lists it.
40	Albutrepenonacog alfa	Ν	Blood-related products except Fibrin Sealants	2.11	Group	Haemophilia B				
			Growth Hormone & growth hormone	0.5.4		Growth hormone				An albumin/somatropin fusion protein that acts as a growth hormone receptor agonist. Commissioner changed to NHSE as per V11 s/sheet
41	Albutropin	N	Receptor Antagonist	6.5.1	Individual	deficiency adult onset				2018.
42	Aldesleukin	Ν	drugs Drugs affecting the	8.2.4	Individual	cancer				
43	Alemtuzumab	Ν	immune response	8.2.3	Individual	Multiple Sclerosis				
			Drugs affecting the		la distala a l	Pre-transplant				
44	Alemtuzumab	N	immune response Drugs affecting the	8.2.3	Individual	immunosuppression				
45	Alemtuzumab	Ν	immune response	8.2.3	Individual	CLL				
			Drugs affecting the							
46	Alemtuzumab	Ν	immune response	8.2.3	Individual	BehÇet's Syndrome				Added to match NHSE s/sheet
47	Alglucosidase alfa (Lumizyme® Myozyme®)	Ν	Lysosomal Storage Disorder drugs	9.8.1	Group	Pompe disease - late onset (pts 8yrs & over)				
48	Alipogene Tiparvovec	Ν	Drugs used in Metabolic disorders	9.8	Individual	Hyperlipoproteinaemia				
49	Alirocumab	С	Lipid regulating drugs	2.12	Individual	Hypercholesterolaemia	Monitored	NICE TA393	https://www.nice.org.uk/guid ance/ta393	

			Viral Hepatitis (B&C) &				[
			respiratory Syncytial							
50	Alisporivir	Ν	Virus	none	Group	Hepatits C				
					'	Severe chronic hand			http://guidance.nice.org.uk/T	
51	Alitretinoin	С	Skin Conditions	13.5.1	Individual	eczema in adults	Monitored	NICE TA177	<u>A177</u>	
			Drugs used in			Alpha-1 anti-trypsin				
52	Alpha-1 Antitrypsin	N	Metabolic disorders	3	Individual	deficiency: Emphysema				Intravenous and inhaled
						Alpha-1 anti-trypsin				
						deficiency: Type 1				
50	Alpha 1 Antitrupain	Ν	Drugs used in	C 1	ا میں اور برا	diabetes mellitus in				Introveneure
53	Alpha-1 Antitrypsin Alpha-Mannosidase	IN	Metabolic disorders Lysosomal Storage	6.1	Individual	children.				Intravenous
54	recombinant human	Ν	Disorder drugs	none	Group					
54		i N		none	Group					Removed from national list.
										However, a locally agreed tariff
										for hyper acute stroke units has
									http://guidance.nice.org.uk/T	agreed that this can be re-
55	Alteplase	С				Acute ischaemic stroke	Monitored	NICE TA264	A264	charged to commissioners.
			Vasodilator							
			antihypertensive							
			drugs/Pulmanory							
56	Ambrisentan	N	Arterial Hypertension	2.5.1	Individual	Pulmonary hypertension				
						Lambert-Eaton				
						Myasthenic Syndrome or				
	Amifampridine		Neuromuscular			Congenital Myasthenia				
57	phosphate	N	Disorders	10.2.1	Individual	Gravis				
50	A miles sin Inholation	С	Antibastarial Drugs	5.1.4	ا میں اور برا	Ventilator Assisted	Individual Funding			
58	Amikacin Inhalation	ل د	Antibacterial Drugs	5.1.4	Individual	Pneumonia	Individual			
59	Amikacin Inhalation	N	Antibacterial Drugs	5.1.4	Individual	Cystic fibrosis	Funding			Added to match NHSE s/sheet
55	Amikacin innalation		Antibacterial Drugs	5.1.4	Individual	Management of cystic				Added to match whoe sysheet
60	Amikacin liposomal	Ν	Antibacterial Drugs		Individual	fibrosis				
						Licensed indications				
						and/or Consultant				
61	Amphotericin liposomal	N	Antifungals	5.2.3	Individual	Microbilogist approval only				
										Not recommended by NICE for
		-				Rheumatoid Arthritis,			http://www.nice.org.uk/guida	RA; former TA72 now
62	Anakinra	C	Cytokine modulators	10.1.3	Group	rheumatology [adults]	Exceptional case	NICE CG79	nce/CG79	incorporated into updated CG79
63	Anakinra	N	Cytokine modulators	10.1.3	Group	Juvenile Arthritis				
64	Anakinra	N	Cytokine modulators	10.1.3	Group	Paediatric indications				
						Specialist				
65	Anakinra	N	Cytokine modulators	10.1.3	Group	Autoinflammatory disease			1	
00		IN		10.1.0		Cryopyrin Associated			1	
66	Anakinra	Ν	Cytokine modulators	10.1.3	Group	Periodic Syndrome				
		N	,	5.2.4		· · · · ·	1	1	1	
67	Anidulafungin	N	Antifungals	5.2.4	Individual	Invasive candiasis				
						Licensed indications (Not			1	
	Antihaemophilic					all blood products are			1	
	Factor/von Willebrand		Blood-related products			listed in the BNF, but they			1	
68	Factor Complex	Ν	except Fibrin Sealants	2.11	Group	are all excluded from PbR)			1	
			Drugs used in		·					
1			hypoplastic,						1	
			haemolytic and renal						1	
69	Antilymphocyte globulin	N	anaemias	9.1.3	Group	Licensed indications				

										Pseudomonas aeruginosa in
										ventilated ICU patients - to
	Anti-pseudomonas					Pseudomonas Aeruginosa	Individual			prevent infections in Cystic
70	aeruginosa IgY	Ν	Antibacterial Drugs	5.1.7	Individual	Vaccine	Funding			Fibrosis patients
						Licensed indications (Not				
						all blood products are				
						listed in the BNF, but they				
71	Antithrombin III	Ν	Blood related products	2.11	Group	are all excluded from PbR)				
			Drugs used in							
			hypoplastic,							
	Antithymocyte		haemolytic and renal							
72	Immunoglobulin	Ν	anaemias	8.2.2	Group	Licensed indications				
									https://www.nice.org.uk/guid	
73	Apremilast	С	Cytokine modulators	none	Group	Psoriasis	Monitored	NICE TA419	ance/ta419	NICE TA now positive
							Exceptional case;			
							will change to			
							monitored if final			
							NICE guidance			Being re-evaluated by NICE;
						1	becomes		1	Final Appraisal Determination
							positive. Due		https://www.nice.org.uk/guid	document positive (subject to
74	Apremilast	С	Cvtokine modulators	none	Group	Psoriatic arthritis	February 17.	NICE TA372	ance/ta372	criteria)
75	Apremilast	N	Cytokine modulators	none	Group	Paediatric indications	robidary in.			omonay
	, promision	11	Intravenous/subcutane			Antibody deficiency		1	1	
			ous human normal			syndromes, Immunology,				
76	Aragam	Ν	immunoglobulins	14.5.1	Group	Neurology				
70	Aragam	IN	Lysosomal Storage	14.3.1	Group	Neurology				
77	Asfotase alfa	Ν	Disorder drugs	9.8.1	Group	Hypophosphatasia				
//	Asiolase alla	IN		9.8.1	Group	Hypophosphatasia				
			Viral Hepatitis (B&C) &							
			respiratory Syncytial		_					
78	Asunaprevir	Ν	Virus	5.3.3	Group	Hepatits C				
			Viral Hepatitis (B&C) &							
	Asunaprevir +		respiratory Syncytial							NHSE s/sheet shows this
79	Daclatasvir	N	Virus	5.3.3	Group	Hepatits C				combination.
			Viral Hepatitis (B&C) &							
	Asunaprevir + Beclabuvir		respiratory Syncytial							This combination not on official
80	+ Daclatasvir	N	Virus	5.3.3	Group	Hepatits C				lists but is being trialled.
			Drugs affecting the			Systemic lupus				
81	Atacicept	N	immune response	8.2.2	Individual	erythematosus (SLE)				
			Neuromuscular							
82	Ataluren	Ν	Disorders	3	Individual	Cystic fibrosis			1	
			Neuromuscular			Duchenne Muscular	1			
83	Ataluren	Ν	Disorders	10.2	Individual	Dystrophy			1	
			AIDS/HIV			HIV in combination with				
84	Atazanavir	Ν	antiretrovirals	5.3.1	Group	other anti-retroviral drugs				
			AIDS/HIV			HIV in combination with		İ	1	
85	Atazanavir and Cobsistat	Ν	antiretrovirals	5.3.1	Group	other anti-retroviral drugs				Added to match NHSE s/sheet
						Age-related macular			1	
						degeneration (AMD);			1	
			Subfoveal choroidal			geographic atrophy				
86	Avacincaptad pegol	С	neovascularisation		Individual		Individual funding			2019
00	Avacilicapiau pegol		neovasculansalion		munuda	(advanced <u>dry</u> -type AMD).				2013
1						Thrombocytopenic			1	
1			Platelet Disorder			purpura (ITP),			1	
87	Avatrombopag	С	Drugs	9.1.4	Individual	thrombocytopenia	Individual funding			
	, trailonibopag	<u> </u>	2.090			First line prevention of			1	
88	Avoralstat	Ν	Allergic Emergencies	3.4.3	Individual	hereditary angiodema				
00	rivoraistat	IN	Miergie Littergenoies	0.4.0	mumuual	noreuliary anyiouenna	1			

			Protein kinase					1		
89	Axitinib	Ν		8.1.5	Individual					
09	Axiumi	IN	Myelodysplastic	0.1.5	Individual					
90	Azacitidine	Ν	Syndrome	8.1.3	Individual					
50	Aztreonam Lysine		Bynaronne	0.1.0	Individual	Management of cystic				
91	[=nebulised]	N	Antibacterial Drugs	5.1.2.3	Individual	fibrosis				
				0		Rheumatoid arthritis - selective JAK1 and JAK2			https://www.nice.org.uk/guid ance/ta466 http://gmmmg.nhs.uk/docs/g uidance/GMMMG-RA-	
92	Baricitinib	С	Immunomodulating drugs	10.1.3	Individual	inhibitor	Monitored	NICE TA466	pathway-v4-1.pdf	NICE TA referenced
92	Danciunio	C	Corticosteroids and	10.1.5	Individual	Prophylaxis of acute organ	wormored	NICE TA400	patriway-v4-1.pdi	NICE TA leferenced
			other			rejection - Adolescents				
93	Basiliximab	Ν		8.2.2	Individual	and children				
00	Buomiximus		Viral Hepatitis (B&C) &	0.2.2	Individual					Annex C has inserted this as a
			Respiratory Syncytial							separate entry but only
94	Beclabuvir	N		5.3.3	Group	Hepatitis C				combination products in NDO.
• ·	200102011		1.00	0.0.0	0.000	Extensively drug resistant				Two rows to match NHSE
95	Bedaguiline	N	Antituberculosis drugs	5.1.9	Individual	ТВ				s/sheet
				-		1	1			Two rows to match NHSE
96	Bedaquiline	N	Antituberculosis drugs	5.1.9	Individual	Multi drug resistant				s/sheet
97	Begelomab	N	Malignant disease and immunosuppression	8	Individual	Graft versus host disease (GvHD)				Marketing application withdrawn pending receipt of further data. Included only for completeness and match to national list.
			David official the state			Prevention of organ				
98	Deleteent	N	Drugs affecting the	8.2.2	ا م بان شایر م	rejection following renal				
98	Belatacept	N	immune response Drugs affecting the	8.2.2	Individual	transplant Systemic lupus				
99	Belimumab	Ν	immune response		Individual	erythematosus (SLE)				
33	Delimonad	IN			Individual	Asthma - uncontrolled on				
			Allergen			high-dose inhaled corticosteroid + LABA - in				Monoclonal antibody binding to the interleukin-5 receptor that
100	Benralizumab	N	Immunotherapy		Group	adults and adolescents				depletes eosinophils. 2017
101	Benralizumab	с	Allergen Immunotherapy		Group	COPD	Individual funding			Monoclonal antibody binding to the interleukin-5 receptor that depletes eosinophils. 2019
_						Respiratory Distress				
102	Beractant	N	Pulmonary surfactants	3.5.2	Individual	Syndrome				
103	Betaine	N	Drugs used in Metabolic disorders	9.8.1	Individual	Homocystinuria, tetrahydrofolate reductase deficiency, cobalamin cofactor metabolism.				
									http://qmmmg.nhs.uk/docs/g uidance/GMMMG%20recom mendation%20Bevacizumab %20wAMD%20Nov%2015.p	
104	Bevacizumab	С		11.8.2	Individual	AMD	Individual funding	GMMMG	dt	
105	Bevacizumab	N		8.1.5	Individual	Cancer				
106	Bevacizumab	N	Antineoplastic drugs	8.1.5	Individual	Neurofibromatosis				
407	N					Myopathy sporadic inclusion body myositis				
107	Bimagrumab	N	Cytokine modulators	0.0	Group	(sIBM) - first-line				
108	Biotin	N	?	9.6	Individual	Multiple Sclerosis				
100	Dliaihimaad	N	Outoking madulater-	10 1 2	Crown	Systemic lupus				
109	Blisibimod	N	Cytokine modulators	10.1.3	Group	erythematosus				
110	Boceprevir	N	Viral Hepatitis (B&C) & respiratory Syncytial Virus	5.3.3	Group	Hepatits C				
110	Docepievii	IN	viius	0.0.0	Joioup	riepaulo U	L	l	I	

111	Bortezomib	N	Antineoplastic drugs	8.1.5	Individual	Cancer				
1						Organ rejection post				
112	Bortezomib	N	Antineoplastic drugs	8.1.5	Individual	kidney transplant				Added to match NHSE s/sheet
l			Vasodilator							
ł			antihypertensive							
ł			drugs/Pulmanory							
113	Bosentan	N		2.5.1	Individual	Pulmonary hypertension				
1			Vasodilator							
ł			antihypertensive							
ł			drugs/Pulmanory							
114	Bosentan	N		2.5.1	Individual	Digital ulcers				
ł			Protein kinase			Chronic myelogenous				
115	Bosutinib	N	inhibitors	8.1.5	Individual	leukaemia (CML)				
ł			Torsion Dystonias and							
		0	other involuntary		0	Prevention of headaches		Migraine only:	http://guidance.nice.org.uk/T	
116	Botulinum toxin	С	movements	4.9.3	Group	in chronic migraine.	Monitored	NICE TA260	11200	
ł									When used in line with local	
ł			Tantian Dustanian and						GM policy: GM	
1			Torsion Dystonias and						Hyperhidrosis Policy v1.0	
			other involuntary					~ ~ ~	Final, available from CCG	
117	Botulinum toxin	С	movements	4.9.3	Group	Hyperhidrosis	Monitored	GM	websites	
ł			Torsion Dystonias and			All other uses including	Monitored /		http://gmmmg.nhs.uk/docs/g	
110	Detailing to i	_	other involuntary	100	0	torsion dystonias,	Individual	014	uidance/Botulinum-toxin-	
118	Botulinum toxin	С	movements	4.9.3	Group	involuntary movements,	Funding	GM	policy-1-0-080218.pdf	Please check local GM policy.
ł			Torsion Dystonias and							
			other involuntary		0					
119	Botulinum toxin	N	movements	4.9.3	Group	Focal spasticity in children				
1			Torsion Dystonias and							
100			other involuntary		0	Intravesical use in spinal				
120	Botulinum toxin	N	movements	4.9.3	Group	cord injury				
ł						In allogeneic				
			Cytomegalovirus			haematopoietic stem cell				
121	Brincidofovir	N	infection	5.3.3.2	Individual	transplant				
ł										NICE TA expected 30/5/18. If
1										positive, category changes to
1										monitored when used in line with
1										the TA.
1										NHSE states on V11 that it will
ł										be responsible for paediatric
1			las as un a su a duda tin s			Desire is fill 47 as seater	the all of all the l			indications should a positive
100	Due de luire e la	0	Immunomodulating	10 5 0	La alla dale al	Psoriasis [IL-17 receptor	Individual			NICE TA become available for
122	Brodalumab	С	drugs	13.5.3	Individual	blocker]	Funding			adult indications.
100	Drodolumoh	С	Immunomodulating	10.1.2	ا میں نامانی ما	Psoriatic arthritis [IL-17	Individual			policy will be required. SPS
123	Brodalumab	U U	drugs	10.1.3	Individual	receptor blocker]	Funding			suggests 2018
I			Subfoveal choroidal			Neovascular (wet) age- related macular	Individual			
124	Brolucizumab	с		11.8.2	Individual	degeneration (AMD)	Funding			
124	Brolucizumap		neovascularisation	11.8.2	mulvidual	Acute attack and	Funding			NOT in SPS
ł										
125	C1 Esterase inhibitor	Ν	Allergic Emergencies	3.4.3	Individual	prophylactic treatment of hereditary angiodema				
120	CI ESIGIASE INNIDIUI	IN	Allergic Emergencies	3.4.3	muiviuual	Treating gouty arthritis				<u> </u>
ł										
ł	Canakinumab		Immunomodulation			attacks and reducing the			http://guidanaa piaa ara uk/T	NICE TAG terminated - unable
106		с	Immunomodulating	0.2.4	Individual	frequency of subsequent	Eventional coord		<u>nπp://guidance.nice.org.uk/1</u> A281	
126	llaris	U U	drugs	8.2.4	Individual	attacks	Exceptional case	NICE TA281	<u>AZ01</u>	to recommend use
ł						Autoimmune disorders				
ł	Canakinumab		Immunomedulation			[e.g. CAPS, MWS,				
		l	Immunomodulating	8.2.4	Individual	NOMID, CINCA, FCAS, FCU]				
107	llorio									
127	llaris Conskinumsh	N	drugs	8.2.4	Individual	FCOJ				
127 128	Ilaris Canakinumab Ilaris	N N	Immunomodulating	8.2.4	Individual	Juvenile arthritis				

			Drugs used in			Urea cycle disorders,				
129	Carglumic acid	Ν	Metabolic disorders	9.8.1	Individual	Hyperammonaemia				
						Primary and secondary				
						carnitine deficiency,				
						haemotology /				
	o		Drugs used in			amminoacid supplement,				
130	Carnitine	N	Metabolic disorders	9.8.1	Individual	renal medicine				
131	Caspofungin	N	Antifungals	5.2.4	Individual					
			Disc disclosed as as durate							
400	Ostridases	N	Blood-related products	0.44	0	Congenital factor XIII A-				
132	Catridecacog	N	except Fibrin Sealants	2.11	Group	subunit deficiency				not in SPS list; drug
										development cancelled.
										Included here to match national
133	Ceralifimod	Ν			Group	Multiple sclerosis (MS)				list.
155	Ceraiiiiniou	IN			Group	Neuronal ceroid				1151.
						lipofuscinosis - late				
			Central Nervous			infantile type 2 (CLN2), a				
134	Cerliponase alfa	Ν	System		Individual	form of Batten disease				
135	Certolizumab Pegol	N	Cytokine modulators	10.1.3	Group	Any paediatric use				
	Contoinzantab r ogor	11					1		http://www.nice.org.uk/guida	
									nce/ta375	
									100,10010	
									http://gmmmg.nhs.uk/docs/g	
								NICE TA375 / GM	uidance/GMMMG%20RA%2	
						Rheumatoid Arthritis,		Harmonised	0Pathway%2022%20april_2	
136	Certolizumab Pegol	С	Cvtokine modulators	10.1.3	Group	rheumatology,	Monitored	biologics pathway		
					0.00	Rheumatoid Arthritis: for				
						treating rheumatoid				
						arthritis after inadequate				
						response to a TNF-alpha			https://www.nice.org.uk/guid	
137	Certolizumab Pegol	С	Cytokine modulators	10.1.3	Group	inhibitor	Monitored	NICE TA415	ance/ta415	
									http://guidance.nice.org.uk/T	
								NICE TA383 / GM	A383	
								Harmonised		
								Pathway for	http://gmmmg.nhs.uk/docs/g	
								biologics in AS	uidance/GMMMG-AS-PsA-	
138	Certolizumab Pegol	С	Cytokine modulators	10.1.3	Group	Ankylosing spondylitis	Monitored	and PsA.	pathway-Final-v4.pdf	
									https://www.nice.org.uk/guid	
									ance/ta445	
								GM Harmonised	_	
								Pathway for	http://gmmmg.nhs.uk/docs/g	
								biologics in AS	uidance/GMMMG-AS-PsA-	
139	Certolizumab Pegol	С	Cytokine modulators	10.1.3	Group	Psoriatic arthritis	Monitored	and PsA.	pathway-Final-v4.pdf	NICE TA referenced
		-				Crohn's Disease,				
140	Certolizumab Pegol	С	Cytokine modulators	10.1.3	Group	gastroenterology	Individual funding			
141	Cetuximab	N	Antineoplastic drugs	8.1.5	Individual	Cancer				
						Cerebrotendinous				A lipid storage disorder.
			Drugs used in			xanthomatosis				Expected Q4 2016.
142	Chenodeoxycholic acid	Ν	Metabolic disorders		Group	Primary Biliary Cirrhosis				
4.40	Oh allia a sid		Drugs used in		Log altration 1	Inborn errors in primary				
143	Cholic acid	N	Metabolic disorders	none	Individual	bile acid synthesis	ł			
	Olda faulia		An the instant		Log altration 1	Cytomegalovirus				
144	Cidofovir	N	Antiviral drugs	5.3.2.2	Individual	infections	ł			
4.45			Antihantari J.D.	E 4 40	Log altration 1	Decembra de la				Only when given by inhalation /
145	Ciprofloxacin inhalation	N	Antibacterial Drugs	5.1.12	Individual	Bronchiectasis				nebulisation.
140	Cincefleure ein lin	N 1	Antihontorial Davas	E 4 40	المعالية بأعاد - ا	Dropohiost'-				Only when given by inhalation /
146	Ciprofloxacin liposomal	N	Antibacterial Drugs	5.1.12	Individual	Bronchiectasis	ł			nebulisation.
147	Cladribine	N	Immunomodulating drugs	8.1.3	Individual	Multiple Sclerosis				
									1	

			Immunomodulating			Pulmonary Langerhans				
148	Cladribine	N	drugs	8.1.3	Individual	histiocytosis				
			AIDS/HIV			HIV in combination with				
149	Cobicistat	N	antiretrovirals		Group	other anti-retroviral drugs				
			Drugs affecting the			Ulcerative colitis (UC)				
150	Cobitolimod	С	immune response		Individual	refractory, 3rd line	Individual funding			2019
	Co-careldopa internal		Neurodegenerative			Advanced parkinsons (via				
151	tube intestinal gel	Ν	conditions	4.9.1	Individual	PEG)				
	Ť					Management of cystic				
152	Colistimethate sodium	Ν	Antibacterial Drugs	5.1.7	Individual	fibrosis				
-	Collagenase (outpatient			-					https://www.nice.org.uk/guid	Use in line with NICE / GM
153	use only)	С	Enzymes	10.1.3	Individual	Dupytren's contracture	Monitored	NICE TA 459	ance/ta459	policy.
		-				Frozen Shoulder /				
	Collagenase (outpatient					Peyronie's Disease / any				Any other use that's not
154	use only)	С	Enzymes	10.1.3	Individual	other use	Individual funding			Dupytren's in line with GM policy
134	Conestat alfa	U	Liizyiiles	10.1.5	Individual	other use				Dupytien's in line with Olvi policy
	(Recombinant C1					Acute attack of hereditary				
155	Esterase inhibitor)	Ν	Allergic Emergencies	3.4.3	Individual	angiodema				
155	Esterase initibility	IN		3.4.3	Individual	angiodenia				
450			Protein kinase							
156	Crizotinib	N	inhibitors	8.1.5	Individual	Cancer				
			_ <u> </u>		1					Expected 2018. Policy will be
	Darvadstrocel (CX601,		Drugs affecting the			Perianal fistulas in Crohn's				required. Allogeneic, expanded,
157	Alofisel)	С	immune response	1.5.3	Individual	Disease	Individual funding			adipose-derived stem cells
	Cysteamine bitartrate									
	(also known and shown		Drugs used in							
158	as mercaptamine)	N	Metabolic disorders	9.8.1	Individual	Nephropathic cystinosis				
										SPS says will be NHS England
	Cysteamine		Drugs used in			Cystinosis [Corneal				funded. Dropcys eye drops
159	hydrochloride	N*	Metabolic disorders	11.1	Individual	cystine crystals]				(0.1% solution)
			Protein kinase							
160	Dabrafenib	N	inhibitors	8.1.5	Individual	Cancer				
			Viral Hepatitis (B&C) &							
			respiratory Syncytial							
161	Daclatasvir	Ν	Virus	5.3.3	Individual	Hepatitis C				
-			Corticosteroids and							
			other-							No information regarding this
162	Daclizumab	N	immunosuppressants	8.2	Group	Organ transplant				use in SPS so removed.
	DaoilEdillab		Corticosteroids and	0.2	Cicup	organtianopiant				
			other-							Drug withdrawn. To be removed
163	Daclizumab	N		8.2	Group	Multiple Sclerosis				at next refresh.
105	Daciizaniab	TT	minunosuppressants	0.2	Croup					Not on NHSE V11 s/sheet yet
										was on V10 and no note.
						Haemophillia A				Treatment of haemophilia is
101	Demostration alternation	N 1 *	Tib size a batica a	0.44	La alla dale da l					
164	Damoctocog alfa pegol	N*	Fibrinolytics	2.11	Individual	prophylaxis and treatment	+			commissioned by NHSE.
105	Deruneutin	K 1	AIDS/HIV	5.2.4	Crown	HIV in combination with				
165	Darunavir	N	antiretrovirals	5.3.1	Group	other anti-retroviral drugs				
			AIDS/HIV			HIV in combination with				
166	Darunavir + cobicistat	N	antiretrovirals	5.3.1	Group	other anti-retroviral drugs				included to match NHSE list
			Viral Hepatitis (B&C) &		1					
			Respiratory Syncytial		1					
167	Dasabuvir	N	Virus	5.3.3	Group	Hepatitis C				
			Protein kinase							
168	Dasatinib	N	inhibitors	8.1.5	Individual	Cancer				
			Myelodysplastic							
169	Decitabine	Ν	Syndrome	8.1.3	Individual	Cancer				
			Drugs used in	1						
			hypoplastic,		1	Iron chelation in				
			haemolytic, and renal		1	thlassaemia and sickle				
			anaemias - Iron		1	cell: myelodysplastic				CCGs commission use in
170	Deferasirox	С	overload	9.1.3	Group	syndrome	Monitored			myelodysplastic syndrome
170	Deletasilox	0	ovendau	0.1.0	Sloup	Synarome	Monitoreu	1		myciouyspiastic synurome

						1	1	1		1
			Drugs used in							
			hypoplastic,							
			haemolytic, and renal			Iron chelation in				
			anaemias - Iron			thlassaemia and sickle				
171	Deferasirox	Ν	overload	9.1.3	Group	cell				
			Drugs used in							
			hypoplastic,			Iron chelation in				
			haemolytic, and renal			thlassaemia and sickle				
			anaemias - Iron			cell: myelodysplastic				CCGs commission use in
170		0			0					
172	Deferiprone	С	overload	9.1.3	Group	syndrome	Monitored			myelodysplastic syndrome
			Drugs used in							
			hypoplastic,							
			haemolytic, and renal			Iron chelation in				
			anaemias - Iron			thlassaemia and sickle				
173	Deferiprone	N	overload	9.1.3	Group	cell				
			Blood-related products			Hepatic veno-occlusive				
174	Defibrotide	N	except Fibrin Sealants	none	Crown	disease				
174	Denbroude	IN	except Fibrin Sealants	none	Group					
						Extensively drug resistant				Two rows to match NHSE
175	Delamanid	N	Antituberculosis drugs	5.1.9	Individual	ТВ				s/sheet
										Two rows to match NHSE
176	Delamanid	N	Antituberculosis drugs	5.1.9	Individual	Multi drug resistant TB				s/sheet
			Drugs used in							
			hypoplastic,			Iron chelation in				
			haemolytic, and renal			thlassaemia and sickle				
			anaemias - Iron			cell: myelodysplastic				CCGs commission use in
177	Desferrioxamine	С	overload	9.1.3	Group	syndrome	Monitored			myelodysplastic syndrome
1//	Desternoxamine	U U		9.1.3	Group	syndrome	Monitored			myelodysplastic syndrome
			Drugs used in							
			hypoplastic,							
			haemolytic, and renal			Iron chelation in				
			anaemias - Iron			thlassaemia and sickle				
178	Desferrioxamine	N	overload	9.1.4	Group	cell				
						Macular oedema				
	Dexamethasone					secondary to retinal vein			http://guidance.nice.org.uk/T	
179	intravitreal implant	С	Macular Oedema		Individual	occlusion	Monitored	NICE TA229	A229	
175	Dexamethasone	Ŭ			Individual	occidatori	Monitorea		https://www.nice.org.uk/guid	
100		С	Macular Oedema		العطائب بأطريها	Diabetic macular oedema	Monitored		ance/ta349	
180	intravitreal implant	U U	Macular Oederna		Individual		Monitored	NICE TA349	ance/ta349	
						Inflammation of the				
						posterior segment of the				
	Dexamethasone					eye presenting as non-			https://www.nice.org.uk/guid	
181	intravitreal implant	С	Macular Oedema		Individual	infectious uveitis	monitored	NICE TA460	ance/ta460	
			Immunomodulating			Anthracycline				
182	Dexrazoxane	N	drugs	8.1	Group	cardiotoxicity				
<u> </u>		···	Immunomodulating			Anthracycline	1	1		
183	Dexrazoxane	Ν	drugs	8.1	Group	extravasation				
100		IN	Bone morphogenetic	0.1	Group		+		1	
104					ا م بان زمان ما	Complex epiral interv				
184	Dibotermin alfa	N	protein	none	Individual	Complex spinal injury				
			Bone morphogenetic			Orthopaedics / other than				
185	Dibotermin alfa	С	protein	none	Individual	complex spinal surgery	Individual funding			
			AIDS/HIV			HIV in combination with				
186	Didanosine	N	antiretrovirals	5.3.1	Group	other anti-retroviral drugs				
·				16.3.2 (BNF		1				
1		1	Poisoning	70)	Individual	Digoxin toxicity	Monitored			
187	Digoxin immune fab	C.								
187	Digoxin immune fab	С	1 bisbilling	,						
187	Digoxin immune fab	С	Ŭ	,		Dermatology: plaque				
			Immunomodulating	, , , , , , , , , , , , , , , , , , , ,		psoriasis, moderate to			https://www.nice.org.uk/guid	
187 188	Digoxin immune fab Dimethyl fumarate	c c	Immunomodulating drugs	13.5	Individual	psoriasis, moderate to severe	Monitored	NICE TA475	https://www.nice.org.uk/guid ance/ta475	
188	Dimethyl fumarate	с	Immunomodulating drugs Immunomodulating			psoriasis, moderate to severe Multiple Sclerosis,	Monitored	NICE TA475		
			Immunomodulating drugs Immunomodulating drugs	13.5 8.2.2	Individual	psoriasis, moderate to severe Multiple Sclerosis, neurology	Monitored	NICE TA475		
188	Dimethyl fumarate	с	Immunomodulating drugs Immunomodulating			psoriasis, moderate to severe Multiple Sclerosis,	Monitored	NICE TA475		

			AIDS/HIV			HIV in combination with				
191	Doravirine	Ν	antiretrovirals	5.3.2	Group	other anti-retroviral drugs				
						Management of cystic				
192	Dornase alfa	N	Mucolytics	3.7	Individual	fibrosis				
193	Dornase alfa	N	Mucolytics	3.7	Individual	Primary ciliary dyskinesia				Added to match NHSE s/sheet
100			Neuromuscular	0.1	individual	Duchenne Muscular				
194	Drisapersen	Ν	Disorders	10.2	Individual	Dystrophy				
195	Dupilumab	С	Drugs affecting the immune response		Group	Atopic dermatitis; moderate-to-severe	Individual funding			GMMMG recommendation in production; please consult when available pending NICE TA due 01/08/18
196	Dupilumab	N	Drugs affecting the immune response		Group	Asthma; persistent, add- on therapy	Individual funding			anti-interleukin-4 receptor (IL- 4R) and anti-interleukin-13 receptor (IL-13R) human monoclonal antibody. 2019
						Hereditary angiodema -				Drug withdrawn but still appears
197	Ecallantide	Ν	Allergic emergencies	none	Individual	acute treatment				in NHSE list! IFR required
198	Eculizumab	N	Paroxysmal nocturnal haemoglobinuria	9.1.3	Individual	Organ rejection post transplant C3 glomerulopathy (post transplant)				Added to match NHSE s/sheet
			Paroxysmal nocturnal			Atypical hemolytic uremic				
199	Eculizumab	N	haemoglobinuria	9.1.3	Individual	syndrome				
200	Eculizumab	N	Paroxysmal nocturnal haemoglobinuria	9.1.3	Individual	Paroxysmal nocturnal haemoglobinuria				
200	Louizamab		Drugs affecting the	0.1.0	individual	systemic lupus				
201	Edratide	N	immune response	8.2	Group	erythematosus (SLE)				Not in SPS
			AIDS/HIV			HIV in combination with				
202	Efavirenz	N	antiretrovirals	5.3.1	Group	other anti-retroviral drugs				
203	Efraloctocog alfa	N	Platelet Disorder Drugs		Individual	Haemophilia A				NHSE V11 also states efmoroctocog alfa / Factor VIII FC fusion protein with this drug
204		N	Platelet Disorder	0.44	المطانبة طبيحا	Lleemenkilie D				
204	Eftrenonacog alfa	N	Drugs Viral Hepatitis (B&C) &	2.11	Individual	Haemophilia B				
205	Elbasvir	N	Respiratory Syncytial Virus	5.3.3	Group	Hepatitis C				
206	Eliglustat	Ν	Lysosomal Storage Disorder drugs	9.8.1	Group	Gaucher's Disease				
200	Ligiustat		Lysosomal Storage	5.0.1	Group	Mucopolysaccharidosis IV				
207	Elosulfase alfa	Ν	Disorder drugs	none	Individual	type A				
208	Eltrombopag	с	Platelet Disorder Drugs	9.1.4	Individual	Chronic Immune Thrombocytopenic purpura (ITP)	Monitored	NICE TA293		While eltrombopag and romiplostim are the responsibility of CCGs regardless of the cause of the thromobcytopenia in adults, paediatrics are NHSE responsibility.
		_	Platelet Disorder			Severe aplastic anaemia refractory to immunosuppressive				Terminated NICE appraisal. New row to account for additional
209	Eltrombopag	С	Drugs	9.1.4	Individual	therapy	Exceptional case	NICE TA382	nce/ta382	licensed indication.
210	Elvitegravir	N	AIDS/HIV antiretrovirals	5.3.1	Group	HIV in combination with other anti-retroviral drugs				
210	Ennegravii	IN	anuretrovirais	0.3.1	Group	outer anu-retrovital drugs				

211	Elvitegravir with cobicistat, emtricitabine and tenofovir	N	AIDS/HIV- antiretrovirals	5.3.1	Group	HIV in combination with other anti-retroviral drugs			Not in Annex C but kept in to accord with NHSE s/sheet. No longer listed in NHSE V11 so w be removed for next version.
212	Elvucitabine	Ν	AIDS/HIV antiretrovirals	5.3.1	Group	HIV in combination with other anti-retroviral drugs			
						Hepatitis C infection liver fibrosis after liver			
213	Emricasan	N	AIDS/HIV		Group	transplant HIV in combination with			NHSE V11 adds the combination with tenofovir alafenamide to this entry; will b added as a separate row on ne
214	Emtricitabine	Ν	antiretrovirals	5.3.1	Group	other anti-retroviral drugs			version of this list.
	Emtricitabine with		AIDS/HIV			HIV in combination with			
215	rilpivrine and tenofovir	N	antiretrovirals	5.3.1	Group	other anti-retroviral drugs			
			AIDS/HIV			HIV in combination with			
216	Enfuvirtide	Ν	antiretrovirals	5.3.1	Group	other anti-retroviral drugs			
0.17			Viral Hepatitis (B&C) & respiratory Syncytial						HIV indication removed [not
217	Entecavir	N	Virus Hormone antagonists [not official PbR	5.3.3	Group	Hepatits B			licensed nor on NHSE list]
218	Enzalutamide	Ν	category]	8.3.4.2		Cancer			Added to match NHSE s/sheet
<u>219</u> 220	Epoprostenol	NN	Vasodilator antihypertensive drugs/Pulmonary Arterial Hypertension	2.8.1	Individual	Pulmonary Arterial Hypertension CD22 antigen inhibitor for Systemic lupus erythematosus (SLE)			commissioned by NHSE within specialist centres. All other indications are CCG commissioned [ref. NHSE]
221	Eprodisate	N	Drugs used in hypoplastic, haemolytic and renal anaemias	9.1	Group	Amyloidosis			While NHSE commissions diagnostic service for patients with amyloidosis from Highly Specialist Amyloidosis centres, CCGs commission most treatments [PSS 46]. However NHSE states that it is responsible commissioner for this drug, although it is not routinely commissioned and therefore requires IFRs submitting to NHSE
000	Enteternein alfa		Bone morphogenetic		0				
222	Eptotermin alfa	N	protein Bono morphogonatio	none	Group	Complex spinal injury	Individual		
223	Eptotermin alfa	С	Bone morphogenetic protein	none	Group	Orthopaedics / other than complex spinal surgery	Individual Funding		
224	Erlotinib	Ν	Protein kinase inhibitors	8.1.5	Individual	Cancer			
						Paediatric indications		TA 455 or as per adult TA's (TA103, TA375,	
225	Etanercept	N	Cytokine modulators	10.1.3	Group	(where adult TA available)		TA143, TA199)	

						T		1		For children transitioning to adult
										services and becoming a CCG
									http://gmmmg.nhs.uk/docs/s	commissioning responsibility,
										category is monitored when in
									to-adult-services-statement-	line with the referenced GMMMG
226	Etanercept	Ν	Cytokine modulators	10.1.3	Group	Juvenile arthritis			amended-post-meeting.pdf	guidance.
									http://guidance.nice.org.uk/T	<u>.</u>
									A383	
								NICE TA383 / GM		
								Harmonised	http://gmmmg.nhs.uk/docs/g	
								Pathway for	uidance/GMMMG%20AS%2	
								biologics in AS	0PsA%20pathway%20v4%2	
227	Etanercept	С	Cytokine modulators	10.1.3	Group	Ankylosing spondylitis	Monitored	and PsA.	0FINAL.pdf	
									http://guidance.nice.org.uk/T	
228	Etanercept	С	Cytokine modulators	10.1.3	Group	Psoriasis (plaque)	Monitored	NICE TA103	<u>A103</u>	
									http://gmmmg.nhs.uk/docs/g	
						Psoriasis (plaque) -			uidance/GMMMG-Biologics-	
						sequential use of biologic			pathway-for-psoriasis-v2-	reference to psoriasis pathway
229	Etanercept	С	Cytokine modulators	10.1.3	Group	agents	Monitored	GMMMG	0.pdf	updated
1									http://guidance.nice.org.uk/T	
								NICE TA199 / GM	A199	
								Harmonised		
								Pathway for	http://gmmmg.nhs.uk/docs/g	
								biologics in AS	uidance/GMMMG-AS-PsA-	reference to AS/ PsA pathway
230	Etanercept	С	Cytokine modulators	10.1.3	Group	Psoriatic Arthritis	Monitored	and PsA.	pathway-Final-v4.pdf	updated
									http://www.nice.org.uk/guida	
									nce/ta375	
						Rheumatoid Arthritis, after			http://gmmmg.nhs.uk/docs/g	
	-					failure of conventional		Harmonised	uidance/GMMMG-RA-	reference to GMMMG RA
231	Etanercept	С	Cytokine modulators	10.1.3	Group	DMARDs	Monitored	biologics pathway	pathway-v4-1.pdf	pathway updated
						Rheumatoid Arthritis, after			http://www.idea.com/wiele/T	
						failure of TNF inhibitor, if			http://guidance.nice.org.uk/T	
						rituximab contra-indicated,			A195	
						or as monotherapy if rituximab and		NICE TA195 / GM	http://gmmmg.nhs.uk/docs/g	
						methotrexate contra-		Harmonised	uidance/GMMMG-RA-	reference to GMMMG RA
232	Etanercept	С	Cytokine modulators	10.1.3	Group	indicated	Monitored		pathway-v4-1.pdf	pathway updated
232	Etanercept	C	Cytokine modulators	10.1.3	Group	All other adult indications	Individual funding		patitway-v4-1.put	
233	Ltanercept	C	Cylonine modulators	10.1.3	Gloup	Duchenne muscular	inuividuai tunuing			
			Neuromuscular			dystrophy; amenable to				
234	Eteplirsen	Ν	disorders		Group	exon 51 skipping				
201			AIDS/HIV		Croup	HIV in combination with				
235	Etravirine	Ν	antiretrovirals	5.3.1	Group	other anti-retroviral drugs		1		
<u> </u>						Ulcerative colitis (UC)		1		
1						naive to TNF inhibitors				2019
1						and refractory to or				NHSE states on V11 that it will
1						intolerant of prior				be responsible for paediatric
1						immunosuppressant		1		indications should a positive
1			Drugs affecting the			and/or corticosteroid	Individual			NICE TA become available for
				4 5 0	Individual	treatment	Funding			adult indications.
236	Etrolizumab	С	immune response	1.5.3				1		
236	Etrolizumab	С	immune response Drugs affecting the	1.5.3	individual	Crohn's disease moderate-	Individual			
236 237	Etrolizumab Etrolizumab	<u>с</u> с		1.5.3	Individual					2020
			Drugs affecting the			Crohn's disease moderate- to-severe	Individual Funding			2020
	Etrolizumab		Drugs affecting the immune response							2020
237	Etrolizumab Everolimus	С	Drugs affecting the immune response Protein kinase	1.5.3.	Individual	to-severe				2020
237	Etrolizumab Everolimus	С	Drugs affecting the immune response Protein kinase	1.5.3.	Individual	to-severe Cancer				2020

	Everelizeve		Drotoin kinooo			Renal angiomyolipoma			
0.40	Everolimus	N	Protein kinase	0.4.5	la alla dala al	associated with tubular			
240	Votubia	N	inhibitors	8.1.5	Individual	sclerosis			
						Subependymal giant cell			
						astrocytoma (SEGA) and			
						renal angiomyolipoma			
	Everolimus		Protein kinase			associated with tubular			two indications will be separated
241	Votubia	N	inhibitors	8.1.5	Individual	sclerosis			on next version
								https://www.nice.org.uk/guid	
242	Evolocumab	С	Lipid regulating drugs	2.12	Individual	Hypercholesterolaemia	Monitored	ance/ta394	
						Homozygous familial			
243	Evolocumab	Ν	Lipid regulating drugs	2.12	Individual	hypercholesterolaemia			
									Treatment of adult patients with
									moderate to severe limbal stem
									cell deficiency (defined by the
									presence of superficial corneal
									neovascularisation in at least
						Orphan market exclusivity			two corneal guadrants, with
	Ex-vivo expanded					for "Treatment of corneal			central corneal involvement, and
1	autologous human					lesions, with associated			severely impaired visual acuity),
	corneal epithelial cells					corneal (limbal) stem cell			unilateral or bilateral, due to
	containing stem cells 1			-		deficiency, due to ocular			physical or chemical ocular
244	Holoclar	N		?	Individual	burns"			burns.
						Licensed indications (Not			
						all blood products are			
						listed in the BNF, but they			
245	Factor IX	Ν	Blood-related products	2.11	Group	are all excluded from PbR			
						Licensed indications (Not			
						all blood products are			
						listed in the BNF, but they			
246	Factor VII	Ν	Blood-related products	2 11	Group	are all excluded from PbR			
2.0					0.000				
						Licensed indications (Not			
						all blood products are			
						listed in the BNF, but they			
247	Factor VIIa (Eptacog alfa)	Ν	Blood-related products	2.11	Croup	are all excluded from PbR			
247	Factor vila (Epiacog alia)	IN	BIOOD-TEIALED PTODUCIS	2.11	Group	are all excluded from PDR)		
1						Licensed indications (Not		1	
1						all blood products are		1	
						listed in the BNF, but they			
248	Factor VIII	N	Blood-related products	2.11	Group	are all excluded from PbR)		
1								1	
1						Licensed indications (Not			Not on NHSE V11 s/sheet yet
1						all blood products are		1	was on V10 and no note.
1	Factor VIII Fc fusion					listed in the BNF, but they			Treatment of haemophilia is
249	protein	N*	Blood-related products	2.11	Group	are all excluded from PbR		1	commissioned by NHSE.
						Licensed indications (Not		1	
1						all blood products are		1	
1	Factor VIII inhibitor					listed in the BNF, but they			
250	bypassing factor	Ν	Blood-related products	2.11	Group	are all excluded from PbR		1	
					- / 0 mp			1	
1						Licensed indications (Not		1	
1						all blood products are		1	
						listed in the BNF, but they		1	
251	Factor XIII	Ν	Blood-related products	2.11	Croup	are all excluded from PbR			
251		IN		2.11	Group		4	+	
050	E a na maistin a	N	Neuromuscular	10.0.1	las alla diale carl	Multiple Oplans siz			
252	Fampridine	N	Disorders	10.2.1	Individual	Multiple Sclerosis			

								T		
253	Fasinumab	С	Cytokine Modulators	4.7	Group	Osteoarthritis	Individual Funding			2019
						Licensed indications (Not all blood products are				
						listed in the BNF, but they				Removed from national and this
254	Fibrin sealants (Tisseel)	C	Blood related products			are all excluded from PbR)	Monitored			list for 2017/19
						Licensed indications (Not				
						all blood products are listed in the BNF, but they				
255	Fibrinogen	Ν	Blood related products	2.11	Group	are all excluded from PbR)				
	Fibroblast growth factor 1		Somatostatin			,				
256	gene therapy	N	Analogues	None	Group					
										2019 NHSE states on V11 that it will
										be responsible for paediatric
										indications should a positive
			Drugs affecting the				Individual			NICE TA become available for
257	Filgotinib	С	immune response	1.5.3	Individual	Crohn's disease	Funding			adult indications.
050	Till and the line	0	Drugs affecting the	40.4.0	Les all'ad also a l	Rheumatoid arthritis (RA);	Individual			0010
258	Filgotinib	С	immune response	10.1.3	Individual	moderate-to-severe	Funding			2019 New separate row for use in
			Drugs used in							neutropenia as per NHSE
259	Filgrastim	Ν		9.1.6	Group	Neutropenia				s/sheet
			Drugs used in							
260	Filgrastim	N	neutropenia	9.1.6	Group	Barth Syndrome				
										NHSE states that it is responsible commissioner for
			Viral Hepatitis (B&C) &							this drug. Drug development
			Respiratory Syncytial							discontinued in 2013! Not in
261	Filibuvir	N		5.3.3	Group	Hepatits C				SPS.
			Immunomodulating							
262	Fingolimod	N	drugs	8.2.4	Individual	Multiple Sclerosis				
263	Fitusiran	Ν	Blood-related products	2.11	Individual	Haemophilia				not in SPS
			Intravenous/subcutane			Antibody deficiency				
			ous human normal			syndromes, Immunology,				
264	Flebogamma	N	immunoglobulins	14.5.1	Group	Neurology				
			Intravenous/subcutane ous human normal			Antibody deficiency syndromes, Immunology,				
265	Flebogammadif	Ν	immunoglobulins	14.5.1	Group	Neurology				
						Treatment of diabetic			http://guidance.nice.org.uk/T	
266	Fluocinolone acetonide	С	Macular Oedema	11.4.1	Individual	macular oedema	Monitored	NICE TA301	<u>A301</u>	
						Emergency treatment of			In line with recommendations from	
						poisoning >Other poisons			National Posions	
						>Ethylene glycol and			Information Service	
267	Fomepizole	С	Poisoning	none	Individual	methanol >Fomepizole	Monitored		http://www.npis.org/	
000	Forigerimod acetate		Drugs affecting the		la alla dale en l	Systemic lupus				
268	Lupuzor	Ν	immune response AIDS/HIV	<u> </u>	Individual	erythematosus (SLE) HIV in combination with				
269	Fosamprenavir	Ν	antiretrovirals	5.3.1	Group	other anti-retroviral drugs				
			Cytomegalovirus							
270	Foscarnet	Ν		5.3.2.2	Individual	Cytomegalovirus infection				
										Likely indication is CCG-
						Idiopathic				commissioned (SPS says NHSE). Spleen tyrosine kinase
			Protein kinase			thrombocytopenic purpura	Individual			(Syk) inhibitor.
271	Fostamatinib disodium	С		9.1	Individual	(ITP)	Funding			2018

			AIDS/HIV					1		
272	Fostemsavir	N		5.3.1	Group	HIV infection				2019
						Cluster headache; chronic	Individual			
273	Galcanezumab	С	Cytokine modulators	4.7	Group	and episodic; prevention	Funding			2018
074	Coloonerumah	с		4.7.4	Crown	prevention of episodic	Individual			2010
274	Galcanezumab	U U	Cytokine modulators	4.7.4	Group	migraine Mucopolysaccharidosis VI	Funding			2019
			Lysosomal Storage			[6 = Matoteaux-Lamy				
275	Galsulfase	N		9.8.1	Group	syndrome]				
215	Gaistinase		Intravenous/subcutane	5.0.1	Group	Antibody deficiency				
			ous human normal			syndromes, Immunology,				
276	Gammagard S/D	Ν		14.5.1	Group	Neurology				
	Ť		Intravenous/subcutane			Antibody deficiency				
			ous human normal			syndromes, Immunology,				
277	Gammanorm	N	immunoglobulins	14.5.1	Group	Neurology				
			Intravenous/subcutane			Antibody deficiency				
			ous human normal		-	syndromes, Immunology,				
278	Gammaplex	N	8	14.5.1	Group	Neurology				
			Intravenous/subcutane			Antibody deficiency				
070			ous human normal		~	syndromes, Immunology,				
279	Gamunex	N		14.5.1	Group	Neurology				
280	Ganciclovir	N	Cytomegalovirus infection	5.3.2.2	Individual	Cytomegalovirus infection				
200	Ganciciovii	IN	Intection	5.5.2.2	Individual	Cytomegalovirus miection				
						Non-small cell lung cancer				
			Immunomodulating			(NSCLC) and acute				
281	Ganetespib	Ν		8.2.4	Individual	myeloid leukaemia (AML)				
201			0.090	01211	in a riddai		Individual			
282	Gantenerumab	С	Drugs for dementia	4.11	Individual	Alzheimer's disease	Funding			2019
			Protein kinase				Ŭ			
283	Gefitinib	N	inhibitors	8.1.5	Individual	Cancer				
						Antibody that binds to the				All development discontinued for
						inflammatory cytokine				uveitis. Also trialled in type 2
			Immunomodulating			interleukin-1 beta (IL-1				diabetes mellitus but unlikely to
284	Gevokizumab	N		11.4.2 / 6.1.2.3	Individual	beta). Uveitis				progress in this indication.
005			Immunomodulating			Multiple Sclerosis,				
285	Glatiramer acetate	N		8.2.4	Individual	neurology				
			Viral Hepatitis (B&C) &							
286	Glecaprevir	N	Respiratory Syncytial Virus		Group	Hepatitis C				
200	Glecapievii	11	vitus		Group	For the urgent treatment				
						of methotrexate-induced				NHSE has commissioning policy
287	Glucarpidase	Ν	Poisoning	None	Individual	renal dysfunction				B15/P/a
201	Claudipidado		i cicci ilg		inarridaa	Urea cycle disorders -				210/174
						hyperammonaemia in				
			Drugs used in			adults and children ≥2				
288	Glycerol phenylbutyrate	N	Metabolic disorders	9.8.1	Individual	months of age				
						Licensed indications (Not				
						all blood products are				
	GlycoPEGylated Factor		Blood-related products		-	listed in the BNF, but they				
289	IX	N	except Fibrin Sealants		Group	are all excluded from PbR)				
										For children transitioning to adult
1										services and becoming a CCG
									http://gmmmg.nhs.uk/docs/s	commissioning responsibility,
										category is monitored when in line with the referenced GMMMG
290	Golimumab	N	Cytokine modulators		Group	Any paediatric use		As per adult TAs	amended-post-meeting.pdf	quidance.
290	Gommunian	IN	Cytokine modulators		Group	Any paeulatile use	1	As per audit TAS	amended-post-meeting.pdf	guiuance.

									http://guidance.nice.org.uk/T	
									A497	
									http://gmmmg.nhs.uk/docs/g	
									uidance/GMMMG-AS-PsA-	reference to AS/ PsA pathway
291	Golimumab	С	Cytokine modulators		Group	Ankyosing spondylitis	Monitored	NICE TA497	pathway-Final-v4.pdf	updated
								NICE TA220 / GM	http://guidance.nice.org.uk/T	
								Harmonised	7220	
								Pathway for	http://gmmmg.nhs.uk/docs/g	
								biologics in AS	uidance/GMMMG-AS-PsA-	reference to AS/ PsA pathway
292	Golimumab	С	Cytokine modulators		Group	Psoriatic arthritis	Monitored	and PsA.	pathway-Final-v4.pdf	updated
									http://www.nice.org.uk/guida	
									<u>nce/ta375</u>	
						Rheumatoid arthritis			http://gmmmg.nhs.uk/docs/g uidance/GMMMG-RA-	reference to RA pathway
293	Golimumab	С	Cytokine modulators		Group	(Methotrexate naïve)	Monitored	NICE TA375		updated
200	Goimanab	0	Cytokine modulators			(Metholicxate harve)	Worldored		http://www.nice.org.uk/guida	
									nce/ta375	
						Rheumatoid arthritis (after			http://gmmmg.nhs.uk/docs/g	
		-				the failure of previous anti-			uidance/GMMMG-RA-	reference to RA pathway
294	Golimumab	С	Cytokine modulators		Group	rheumatic drugs)	Monitored	NICE TA375	pathway-v4-1.pdf	updated
	Granulocyte-macrophage					Antibody-positive				
	colony-stimulating factor		Drugs used in			pulmonary alveolar				Not in Annex B1 but in NHSE
295	(Leukine - Import)	Ν	neutropenia			proteinosis				s/sheet
			Viral Hepatitis (B&C) &							
			Respiratory Syncytial							Will be a combination product
296	Grazoprevir	N	Virus	5.3.3	Group	Hepatitis C				with elbasvir.
										Targets IL-23. Possibly available
			Drugs affecting the				Individual			in 2017. Not on NICE's agenda
297	Guselkumab	С	Immune response	13.5.3	Individual	psoriasis	Funding			so may require local evaluation.
			Neuromuscular			Duchenne muscular				
298	Halofuginone	N*	Disorders		Individual	dystrophy				
299	HIV vaccine	N		14	Group	HIV				ļ
			Intravenous/subcutane			Antibody deficiency				
300	Hizentra	N	ous human normal immunoglobulins	14.5.1	Group	syndromes, Immunology, Neurology				
500			Drugs used in	14.0.1	Cloup	Neurology				<u> </u>
301	Human Arginate	Ν		9.8.2	Individual	Hepatic porphyria				
	Human Heterologous		Drugs used in			Urea cycle disorders in				
302	Liver Cells	N	Metabolic disorders	9.8.1	Individual	children				ļ]
	Human Parathyriod		Daving officially a have			n estre en en est	ا بر مان بزمان – ا			
303	hormone-related protein analogue	С	Drugs affecting bone metabolism	6.6.1	Individual	postmenopausal osteoporosis	Individual Funding			This is abaloparatide (row 5)
303	Human Parathyriod	0		0.0.1	mumuual					
	hormone-related protein		Drugs affecting bone			Male and juvenile				
304	analogue	Ν	metabolism	6.6.1	Individual	osteoporosis				This is abaloparatide (row 5)
			Intravenous/subcutane							
			ous human normal							
305	Hyqvia	N	immunoglobulins	14.5.1	Group	_			⁻	<u> </u>]
306	Ibalizumab	N	AIDS/HIV antiretrovirals	5.3.1	Individual					Not in SPS
300		IN	antifettovitais	0.0.1	mumuuai	Hereditary angiodema -				
						acute and prophylactic				Prophylactic treatment added to
307	Icatibant	Ν	Allergic Emergencies	3.4.3	Individual	treatment				accord with V11
			Neuromuscular			Duchenne muscular				
308	Idebenone	N	Disorders	10.2	Individual	dystrophy				

										Separate row now: Not in NHSE
										V11 s/sheet but expected to
										commission as NHSE
			Neuromuscular							commissions for other
309	Idebenone	N*	Disorders	4	Individual	Friedreich's ataxia				neurodegenerative disorders.
						Visual impairment in				Not in NHSE V11 s/sheet but
						adolescent and adult				expected to commission as
						patients with Leber's				NHSE commissions other rare
	Idebenone		Neuromuscular			Hereditary Optic				mitochondrial diseases.
310	Raxone	N*	Disorders	11.8	Individual	Neuropathy (LHON).				Licensed.
			Lysosomal Storage			Mucopolysaccharidosis II				
311	Idursulfase	N	Disorder Drugs	9.8.1	Group	[2]				
										Use in vascular disease is
			Vasodilator							commissioned by NHSE within
			antihypertensive							specialist centres. All other
			drugs/Pulmonary							indications are CCG
312	lloprost (nebulised)	N	Arterial Hypertension	2.5.1	Individual	Pulmonary hypertension				commissioned [ref. NHSE]
			Protein kinase							
313	Imatinib	N	inhibitors	8.1.5	Individual	Cancer				
			Protein kinase							
314	Imatinib	N	inhibitors	8.1.5	Group	Graft versus host disease				
						Non-neurological				
			Lysosomal Storage			manifestations of type I or				
315	Imiglucerase	N	Disorder Drugs	9.8.1	Group	type III Gaucher's disease.				
			AIDS/HIV			HIV in combination with				
316	Indinavir	N	antiretrovirals	5.3.1	Group	other anti-retroviral drugs				
						Paediatric indications				
317	Infliximab	N	Cytokine modulators	10.1.3	Group	(where adult TA available)				
										For children transitioning to adult
										services and becoming a CCG
									http://gmmmg.nhs.uk/docs/s	commissioning responsibility,
										category is monitored when in
										line with the referenced GMMMG
318	Infliximab	N	Cytokine modulators	10.1.3	Group	Juvenile arthritis			amended-post-meeting.pdf	guidance.
					_	Connective tissue disease				
319	Infliximab	N	Cytokine modulators	10.1.3	Group	 interstital lung disease 				
						Crohn's Disease in				
320	Infliximab	N	Cytokine modulators	10.1.3	Group	children		NICE TA187		
321	Infliximab	N	Cytokine modulators	10.1.3	Group	Graft versus host disease				
322	Infliximab	N	Cytokine modulators	10.1.3	Group	Renal	1			
323	Infliximab	N	Cytokine modulators	10.1.3	Group	Sarcoidosis	1			
324	Infliximab	N	Cytokine modulators	10.1.3	Group	Uveitis [adult and child]			ļ	
325	Infliximab	N	Cytokine modulators	10.1.3	Group	Hidradenitis suppurativa				· · · · · · · · · · · · · · · · · · ·
326	Infliximab	N	Cytokine modulators	10.1.3	Group	BehÇet's Syndrome				Added to match NHSE s/sheet
									http://guidance.nice.org.uk/T	
1									A383	
1								NICE TA383 / GM		
								Harmonised		
								Pathway for	http://gmmmg.nhs.uk/docs/g	
1								biologics in AS	uidance/GMMMG-AS-PsA-	reference to GMMMG AS/PsA
327	Infliximab	С	Cytokine modulators	10.1.3	Group	Ankylosing spondylitis	Monitored	and PsA.	pathway-Final-v4.pdf	pathway updated
									http://guidance.nice.org.uk/T	
									<u>A134</u>	
									http://gmmmg.nhs.uk/docs/g	
									uidance/GMMMG-Biologics-	
1	1					1			pathway-for-psoriasis-v2-	reference to GMMMG psoriasis

							1			
									http://gmmmg.nhs.uk/docs/g uidance/GMMMG-Biologics-	
						Psoriasis (plaque) -				
					_	sequential use of biologic			pathway-for-psoriasis-v2-	reference to GMMMG psoriasis
329	Infliximab	С	Cytokine modulators	10.1.3	Group	agents	Monitored	GMMMG	0.pdf	pathway updated
								NICE TA199 / GM		
								Harmonised		
								Pathway for	http://gmmmg.nhs.uk/docs/g	
								biologics in AS	uidance/GMMMG-AS-PsA-	reference to GMMMG As/ PsA
330	Infliximab	С	Cytokine modulators	10.1.3	Group	Psoriatic Arthritis	Monitored	and PsA.	pathway-Final-v4.pdf	pathway updated
									http://www.nice.org.uk/guida	
									nce/ta375	
									http://gmmmg.nhs.uk/docs/g	
						Rheumatoid Arthritis, after		NICE TA375 / GM	uidance/GMMMG%20AS%2	
						failure of conventional		Harmonised	0PsA%20pathway%20v4%2	New row inserted for this
331	Infliximab	С	Cytokine modulators	10.1.3	Group	DMARDs	Monitored	biologics pathway		indication.
									http://guidance.nice.org.uk/T	
									A195	
									<u>,,,,,,,,</u>	
									http://ammma.nhs.uk/docs/a	
						Rheumatoid Arthritis, after			uidance/GMMMG%20RA%2	
						failure of TNF inhibitor, if			0Pathwav%2022%20april 2	
000	le flissing a le	0	Outobing and data as	10.1.0	0		Maniferral			
332	Infliximab	С	Cytokine modulators	10.1.3	Group	rituximab contra-indicated	Monitored	NICE TA195	015.pdf	
						Crohn's Disease,			http://guidance.nice.org.uk/T	
333	Infliximab	С	Cytokine modulators	10.1.3	Group	gastroenterology	Monitored	NICE TA187	<u>A187</u>	
						Moderately to severely				
						active ulcerative colitis				
						after the failure of			http://www.nice.org.uk/guida	
334	Infliximab	С	Cytokine modulators	10.1.3	Group	conventional therapy	Monitored	NICE TA329	<u>nce/ta329</u>	indication for clarity.
						Acute exacerbations of			http://guidance.nice.org.uk/T	
335	Infliximab	С	Cytokine modulators	10.1.3	Group	ulcerative colitis	Monitored	NICE TA163	<u>A163</u>	
						Sub-acute manifestations			http://www.nice.org.uk/guida	
336	Infliximab	С	Cytokine modulators	10.1.3	Group	of ulcerative colitis	Monitored	NICE TA329	<u>nce/ta329</u>	
		C or N, seek								
		guidance if								
337	Infliximab	necessary	Cytokine modulators	10.1.3	Group	All other indications	Individual funding			
			Immunomodulating				-			
338	Interferon alfa	Ν	drugs	8.2.4	Individual	Hepatitis B+C				
			Immunomodulating			· ·				
339	Interferon beta	Ν	drugs	8.2.4	Individual	Multiple sclerosis				
			Intravenous/subcutane			Antibody deficiency	İ	1	1	1
			ous human normal			syndromes, Immunology,				
340	Intratect	Ν	immunoglobulins	14.5.1	Group	Neurology				
341	Isavuconazole	N	Antifungals	5.2	Individual	Fungal infection				
511			, animinguio			Management of cystic				
342	Ivacaftor	Ν	Mucolytics	3.7	Individual	fibrosis				
512			Drugs used in				1	1		1
			hypoplastic,						1	
			haemolytic and renal			Multiple myeloma (MM) /				
242	lyozomih	Ν		015	Croup	amyloidosis				
343	Ixazomib	IN	anaemias	8.1.5	Group				https://www.pice.org.uk/widd	
									https://www.nice.org.uk/guid	
									ance/ta442	
									http://gmmmg.nhs.uk/docs/g	
									uidance/GMMMG-Biologics-	references to NICE and
									pathway-for-psoriasis-v2-	GMMMG psoriasis pathway
344	Ixekizumab	С	Cytokine modulators	13.5.3	Group	Psoriasis	Monitored	NICE TA442	0.pdf	updated

								Spelling error in drug name
								continues on latest national lists.
								May be marketed for this
								indication in 2018. Policy
345 Ixe	xekizumab	С	Cytokine modulators	13.5.3	Group	Psoriatic arthritis	Individual funding	required.
0.10		Ŭ		10.010	Cicup			Spelling error in drug name
								continues on latest national lists.
								SPS suggests this indication not
								until 2019. Policy may be
346 Ixe	xekizumab	С	Cytokine modulators	13.5.3	Group	Ankylosing Spondylitis	Individual funding	required.
			Retinal					Do we need a policy on this?
			disorders/intraocular					Licensed as Omidria 10 mg/mL
	Cetorolac with		lens replacement			Intraocular lens		+ 3 mg/mL concentrate for
347 Ph	henylephrine	С	surgery	11.8.2	Individual	replacement surgery	Individual funding	solution for intraocular irrigation.
			Intravenous/subcutane			Antibody deficiency		
			ous human normal			syndromes, Immunology,		
348 Kid	Kiovig	N	immunoglobulins	14.5.1	Group	Neurology		
			Viral Hepatitis (B&C) &					
			respiratory Syncytial					
349 La	amivudine	N		5.3.1	Group	Hepatitis B		
			AIDS/HIV			HIV in combination with		
350 La	.amivudine	N	antiretrovirals		Group	other anti-retroviral drugs		
						Geographic atrophy		
						secondary to dry age-		
			Subfoveal choroidal			related macular		
351 La	ampalizumab	С	neovascularisation	11.8	Group	degeneration	Individual funding	2019
			Somatostatin					
352 La	anreotide	N	Analogues	8.3.4.3	Group	Cancer		
								NHSE is the responsible
								commissioner when somatropin
								analogues are prescribed in
			Somatostatin					Specialist Centres for indications
353 La	anreotide	N	Analogues	8.3.4.3	Group	Acromegaly		falling outside NICE guidance.
555 La	ameotice	IN	Analogues	0.3.4.3	Group	Congenital		
			Somatostatin			hyperinsulinism - children		
354 La	anreotide	Ν	Analogues	8.3.4.3	Group	only		
554 La	ameonue	IN	Analogues	0.3.4.3	Group	only		
								NHSE has indicated that the
		C or N, seek						responsible commissioner for
		guidance if	Somatostatin			Congenital		this use is the commissioner for
355 La	anreotide	necessary	Analogues	8.3.4.3	Group	hyperinsulinism - adults	Individual funding	the service caring for the patient.
							Licensed	
							indications:	
					1		monitored.	
					1		Unlicensed	
			Somatostatin			Other than NHSE	indications:	
356 La	anreotide	С	Analogues	8.3.4.3	Group	commissioned indications		
		-	Protein kinase				g	
357 La	apatinib	Ν	inhibitors	8.1.5	Individual	Cancer		
	<u> </u>			1	1			Back in Annex B1 so replaced
			Immunomodulating		1			back into this s/sheet. EMA: not
358 La	.aquinimod	N	drugs	8.2.4	Individual	Multiple sclerosis		recommended for approval.
				1	1	Non-neurological		
						manifestations of		
			Lungagemet Charges			Mucopolysaccharidosis I		
	i		Lysosomal Storage			mucopolysacchanuosis i		

										IL-13 inhibitor.
										However, SPS says asthma
										programme discontinued after
			Allergen			Asthma - various possible	Individual			primary outcome not met in a
360	Lebrikizumab	Ν	Immunotherapy		Group	indications	Funding			Phase III clinical trial.
	Ledipasvir* [and in		Viral Hepatitis (B&C) &							
	combination with		Respiratory Syncytial							
361	sofobusvir]	N*	Virus		Group	Hepatitis C				
										POEMS is new to NHSE V13.
			Immunomodulating			Cancer and POEMS				These 2 indications will be
362	Lenalidomide	Ν	drugs	8.2.4	Individual	syndrome				separated on the next version.
			Drugs used in							
363	Lenograstim	Ν	neutropenia	9.1.6	Group	Neutropenia				
	2011091000		Drugs used in	00	oloup	i touti opointa				
364	Lenograstim	Ν	neutropenia	9.1.6	Group	Barth Syndrome				
001	Lonogradam		Cytomegalovirus	0.110	Croup	Bartin Gynaromo				
365	Letermovir	Ν	infection		Group	Cytomegalovirus infection				2018
303	Letermovii	IN				Cytomegalovirus infection				Unique delivery mode (i.e.
										intestinal gel). Not a new drug.
										Arguably duplicates row 151
			Neurodogoporativo							(both descriptions present in
000	Leveler - Ordider -	N I ¥	Neurodegenerative	1.0.4	0	Dedimenta Disesse				
366	Levodopa + Carbidopa	N*	Conditions	4.9.1	Group	Parkinson's Disease				National List).
						Management of cystic				
367	Levofloxacin (inhaled)	Ν	Antibacterial Drugs	5.1.12	Individual	fibrosis				
			Drugs used in		_					
368	Lipegfilgrastim	N	neutropenia	9.1.6	Group	Neutropenia				
			Vasopressin V2			Hyponatraemia and other				
369	Lixivaptan	N	receptor antagonist	6.5.2	Individual	endocrine uses				
						Homozygous familial				
370	Lomitapide	Ν	Lipid regulating Drugs	2.12	Individual	hypercholesterolemia				
						Hepatitis D infection (with				
			Protein kinase			ritonavir)				
371	Lonafarnib	Ν	inhibitors		Group	and / or cancer				2018
			AIDS/HIV			HIV in combination with				
372	Lopinavir with Ritonavir	Ν	antiretrovirals	5.3.1	Group	other anti-retroviral drugs				
						Not in BNF (Ivacaftor				
						shown as BNF 3.7 on list)				
373	Lumacaftor with Ivacaftor	Ν	Mucolytics		Individual	Cystic fibrosis				
										In adults with chronic liver
										disease prior to undergoing
										elective invasive procedures to
	Lusutrombopag		Platelet Disorder							reduce the need for platelet
374	Mulpleta	N*?	Drugs		Individual	Thrombocytopenia				transfusions
0, 1	maprota		Growth Hormone &		marriada				1	
			arowth hormone							
375	Macimorelin	Ν	Receptor Antagonist	6.5	Individual	Growth failure	1			
575		IN	Vasodilator	0.0	mannudai	Growth failure		+		
			antihypertensive							
			drugs/Pulmanory				1			
276	Magitantan	N		2 5 1	Individual		1			
376	Macitentan	N	Arterial Hypertension	2.5.1	Individual	Managamart of outlin				
077						Management of cystic	1			
377	Mannitol (inhaled)	N	Mucolytics	3.7	Individual	fibrosis.				
			AIDS/HIV			HIV in combination with				
378	Maraviroc	N	antiretrovirals	5.3.1	Group	other anti-retroviral drugs				
			Protein kinase							
379	Masitinib	N	inhibitors	8.1.5	Individual	Pancreatic cancer / GIST				

									0000
									2020
									NHSE states on V11 that it will
									be responsible for paediatric
									indications should a positive
			Drugs affecting the						NICE TA become available for
380	Mavrilimumab	С	Immune response	10.1.3	Individual	Rheumatoid arthritis	Individual funding		adult indications.
			Growth Hormone &				Ĭ		
			growth hormone						
381	Mecasermin	Ν		6.7.4	Individual	Growth failure			
001			Allergen	0.1.1	individual				
382	Mepolizumab	Ν		3.4.2	Individual	Asthma			
302	Mepolizumab	IN	Allergen	3.4.2	Inuiviuuai	Astrina			
000	Manakan	N 14		0.4.0	la alla dale en l	Ohuma Ohaanaa ayaa daalaa a			
383	Mepolizumab	N*		3.4.3	Individual	Churg Strauss syndrome	la di dalera l		
			Allergen				Individual		SPS says COPD use is CCG
384	Mepolizumab	С	Immunotherapy	3.4.4	Individual	COPD	Funding		commissioned
									duplicates row 158 but both
	Mercaptamine		Drugs used in						descriptions present in National
385	(cysteamine)	N	Metabolic disorders	9.8.1	Individual	Nephropathic cystinosis			list.
									SPS says use is NHSE
386	Metreleptin	N*	Other endocrine drugs	6.7	Individual	Lipodystrophy			commissioned
387	Metreleptin	N	Other endocrine drugs	6.7	Individual	Dyslipidaemia			as per entry on V11
	·					Invasive candidiasis (risk			
388	Micafungin	Ν	Antifungals	5.2.4	Individual	of liver tumours)			
	·····g···		Lysosomal Storage						
389	Migalastat	Ν		9.8.1	Group	Fabry's disease			
000	Migalastat		District Drugs	5.0.1	Group	Mild to moderate type I			
						Gaucher's disease,			
			Lysosomal Storage			Niemann-Pick type C			
200	Miglugtot	Ν		0.0.4	Crown				
390	Miglustat	N	Disorder Drugs Protein kinase	9.8.1	Group	disease			
004	Manual a Galla	N			0	Pancreatic cancer / myelofibrosis			0010
391	Momelotinib	N	inhibitors		Group	myelotibrosis			2018
			Viral Hepatitis (B&C) &						
			respiratory Syncytial						
392	Motavizumab	N		none	Group	RSV prophylaxis			
			Immunomodulating						
393	Natalizumab	N	drugs	8.2.4	Individual	Multiple sclerosis			
			AIDS/HIV			HIV in combination with			
394	Nelfinavir	N	antiretrovirals	5.3.1	Group	other anti-retroviral drugs			
			AIDS/HIV			HIV in combination with			
395	Nevirapine	Ν	antiretrovirals	5.3.1	Group	other anti-retroviral drugs			
			Protein kinase						
396	Nilotinib	Ν		8.1.5	Individual	Cancer			
	Nintedanib		Immunomodulating						
397	Vargatef	Ν		8.1.5	Individual	Ovarian cancer			
531	Nintedanib	IN	Immunomodulating	0.1.0	individual	Idiopathic pulmonary			+
398	Ofev	Ν		8.1.5	Individual	fibrosis			
290	Nintedanib	IN	Immunomodulating	0.1.0	individual	660101			
200		N		045	المحانية فاسما		.		
399	Vargatef	N		8.1.5	Individual	Non small cell lung cancer			
			Viral Hepatitis (B&C) &						
			respiratory Syncytial						
400	Nitazoxanide	N		none	Group	Hepatits C			
			Drugs used in			Hereditary tyrosinemia			
401	Nitisinone	N		9.8.1	Individual	type 1		 	
			Drugs used in						
402	Nitisinone	N	Metabolic disorders	9.8.1	Individual	Alkaptonuria			
	1		Vasodilator			· ·			
			antihypertensive						
	1		drugs/Pulmanory			Pulmonary arterial			
403	Nitric Oxide	Ν	J	none	Individual	hypertension			
100		14	, atonar riypertension		mannau	ingentension		1	1

				1			-		[
			Blood-related products							
404	Nonacog alpha	Ν	except Fibrin Sealants	none	Group	Haemophillia B				
-0-		1	cxcept r ibiin Ocaianta	none	Croup					
			Blood-related products							
405	Nonacog beta pegol	Ν	except Fibrin Sealants	none	Group	Haemophillia B				
			Intravenous/subcutane			Antibody deficiency				
			ous human normal			syndromes, Immunology,				
406	Normal Immunoglobulin	Ν	immunoglobulins	14.5.1	Group	Neurology				
						Primary biliary cirrhosis /				Q4 2016
	Obeticholic acid		Drugs used in			Non-alcoholic				
407	Ocaliva	Ν	Metabolic disorders		Individual	steatohepatitis (NASH)				2018
			Immunomodulating							
408	Ocrelizumab	Ν	drugs	8.2.4	Individual	Multiple sclerosis				
100		0	Detinel discusions	11.0.0	la alla dale a l	Focal vitreomacular	Man itana d		http://guidance.nice.org.uk/T	
409	Ocriplasmin	С	Retinal disorders	11.8.2	Individual	adhesion (VMA)	Monitored	NICE TA297	A297	
			Intravenous/subcutane ous human normal			Antibody deficiency syndromes, Immunology,				
410	Ostogom	Ν	immunoglobulins	14.5.1	Group	Neurology				
410	Octagam	IN	Platelet Disorder	14.5.1	Group	Neurology				
411	Octocog Alfa	Ν	Drugs	2.11	Group	Haemophilia A				
411		IN	Growth Hormone &	2.11						
			arowth hormone							
412	Octreolin	Ν	Receptor Antagonist	6.5	Individual	Acromegaly				
			Somatostatin							
413	Octreotide	Ν	Analogues	8.3.4.3	Group	Cancer				
			Ŭ							
414	Octreotide	N	Somatostatin Analogues Somatostatin	8.3.4.3	Group	Acromegaly Congenital				NHSE is the responsible commissioner when somatropin analogues are prescribed in Specialist Centres for indications falling outside NICE guidance.
415	Octreotide	Ν	Analogues	8.3.4.3	Group	hyperinsulinism [children]				
416	Octreotide	C or N, seek guidance if necessary	Somatostatin Analogues	8.3.4.3	Group	Congenital hyperinsulinism [adults]	Individual funding			NHSE has indicated that the responsible commissioner for this use is the commissioner for the service caring for the patient.
		nooodany	, indioguoo	0.01.110	Cicup	ing pointe annioni [audito]	ina na a a a a a a a a a a a a a a a a a			
			Somatostatin			Vomitting in palliative care , Entereocutaneous fistula High output stoma	Licensed indications: monitored. Unlicensed indications: Individual funding except the indications listed adjacent for which the category is	http://gmmmg.nh s.uk/docs/subgro ups/sbgrp- hcdsg/Octreotide- gastro- recommendation.		CCG commissioned for non-
417	Octreotide	С	Analogues	8.3.4.3	Group	Refractory diarrhoea	monitored	pdf		cancer use
418	Odanacatib	C	Drugs affecting bone metabolism	6.6.2	Individual	Osteoporosis [post menopausal]	Individual funding			SPS says development discontinued
		Ŭ	Drugs affecting bone							SPS says development
419	Odanacatib	N*	metabolism	6.6.3	Individual	Osteoporosis [men]	Individual funding			discontinued; not in V11
400	Ofatumumah	N	Immunomodulating	8.2.3	العطائبة طبيحا	Canaar				
420	Ofatumumab	N	drugs	0.2.3	Individual	Cancer				

r	11		T		1	I • • • • • • • • • • • • • • • • • •	1			1
						Multiple sclerosis,				
						pemphigus vulgaris,				
			Immunomodulating			chronic lymphocytic				
421	Ofatumumab	N	drugs	8.2.3	Individual	leukaemia (CLL)	Individual funding			
						Cholesterol oxime				
						mitochondrial pore				
			Neuromuscular			modulator for spinal				
422	Olesoxime	Ν	Disorders	10.2	Individual	muscular atrophy.				
						IgE mediated severe				
			Allergen			asthma all persons				
423	Omalizumab	Ν	Immunotherapy	3.4.2	Individual	6years+				
420	Omalizamab	IN	Allergen	5.4.2	Individual	Chronic spontaneous			http://www.nice.org.uk/guida	
424	Omalizumab	С	0	3.4.2	Individual	urticaria	Monitored	NICE TA339	nce/ta339	
424	Ombitasvir with	C	Immunotherapy	3.4.2	Individual	unicana	Monitored	NICE TA339	nce/ta339	
	Paritaprevir with		Viral Hepatitis (B&C) &							
	Ritonavir with Dasabuvir		Respiratory Syncytial		-					
425	+/- ribavirin	N	Virus	5.3.3	Group	Hepatitis C				
										inhibitor of aldosterone synthase
426	Osilodrostat	Ν	Other Endocrine drugs	6.7.3	Group	Cushing's disease				2018
<u> </u>										
427	Ozanimod	Ν	Multiple sclerosis (MS)	8.2	Group	relapsing-remitting				2019
				-		Ulcerative colitis (UC);				
428	Ozanimod	С	IBD	1.5.3	Group	moderate-to-severe active	Individual funding			2020
120	Ozaminou	, v	Protein kinase	1.0.0	Croup		individual randing			2020
429	Pacritinib	Ν	inhibitors	8.1.5	Individual	Myelofibrosis				
423	1 achthhb		Viral Hepatitis (B&C) &	0.1.5	Individual	Wyelolibrosis				
400			respiratory Syncytial							
430	Palivizumab	N	Virus	5.3.5	Group	RSV prophylaxis				
	Para - Aminosalicylic									
431	acid	Ν	Antituberculosis drugs	5.1.9	Individual	Tuberculosis				
										Additional row added for
			Drugs affecting bone			Specialist endocrinology				consistency with NHSE
432	Parathyroid hormone	N	metabolism	6.6.1	Individual	conditions				spreadsheet
			Drugs affecting bone							
433	Parathyroid hormone	С	metabolism	6.6.1	Group	Osteoporosis in women	Individual funding			
	, , , , , , , , , , , , , , , , , , ,						, i i i i i i i i i i i i i i i i i i i			NHSE commissions TPN for
										intestinal failure types II and III
										but CCGs will commission TPN
										for Type I i.e. where the primary
	Parenteral Nutrition (after									medical issue isn't one of sub-
	14 days or where the					Nutritions Trees Listanti				optimal bowel function. Further
	patient is receiving TPN					Nutrition: Type I intestinal				information is provided at the
434	prior to admission)	С	Parenteral Nutrition	9.3	Group	failure	Monitored			foot of the spreadsheet.
										NHSE commissions TPN for
										intestinal failure types II and III
			1							but CCGs will commission TPN
										for Type I i.e. where the primary
	Parenteral Nutrition (after		1							medical issue isn't one of sub-
	14 days or where the									optimal bowel function. Further
	patient is receiving TPN					Nutrition: Types II and III				information is provided at the
435	prior to admission)	Ν	Parenteral Nutrition	10.3	Group	intestinal failure				foot of the spreadsheet.
100		14	Viral Hepatitis (B&C) &							
			Respiratory Syncytial							
436	Paritaprovir	Ν		5.3.3	Group	Hepatitis C				
430	Paritaprevir	IN		0.0.3	Group					
107			Somatostatin							Two rows to match NHSE
437	Pasireotide	Ν		6.3.4.3	Group	Acromegaly			-	s/sheet
1		Ν	Somatostatin Analogues	6.3.4.3	Group	Cushing's disease				Two rows to match NHSE s/sheet
438	Pasireotide									

			Protein kinase							
439	Pazopanib	Ν		8.1.5	Individual	Cancer				
433		IN		0.1.5	Individual	Wet age related macular				
			Subfoveal choroidal			degeneration,			http://guidance.nice.org.uk/T	
440	Pegaptanib	С		11.8.2	Group	opthalmology	Exceptional case	NICE TA155	A155	
0	regaptarilo	0	neovasediansation	11.0.2	Cioup	Neutropenia - where a	Exceptional case		<u>////00</u>	
			Drugs used in			single dose G-CSF is				
441	Pegfilgrastim	Ν	neutropenia	9.1.6	Individual	necessary				
	r ogngradam		Viral Hepatitis (B&C) &	0.1.0	individual	necessary				
			respiratory Syncytial							
442	Peginterferon alfa	Ν		8.2.4	Group	Hepatitis B and C				
	r oginioriori ana		Immunomodulating	0.2.1	Cicup					
443	Peginterferon Beta-1a	Ν	drugs	8.2.4	Individual	Multiple sclerosis				
	g		Immunomodulating							
444	Peginterferon Lambda-1a	Ν		8.2.4	Individual	Hepatitis C				
			0.090	0.2.1	indifieddai					
						Treatment of acute				
			Gout and cytotoxic-			hyperuricaemia in patients				
			induced			with haematological			http://guidance.nice.org.uk/T	
445	Pegloticase	С	hyperuricaemia	10.1.4	Individual	malignancy	Exceptional case	NICE TA291	A291	
. 10	. 09.010000	, ,	Retinal							
			disorders/intraocular							
	Pegpleranib		lens replacement							
446	Fovista	С	surgery	11.8.2	Individual	Wet-AMD	Individual funding			2018
440	i ovisia	0	Growth Hormone &	11.0.2	Individual	Wel-AMD	Individual funding			2010
			growth hormone							
447	Pegvisomant	Ν		6.5.1	Individual	Acromegaly				
447	Fegvisoniant	IN	Receptor Antagonist	0.5.1	Inulviuuai	Acromegaly				N.B. This drug is not in Annex A
						Treatment naïve				(nor was it on last year's list) but
			Immunomodulating			melanoma (unresectable,				is included here to match NHSE
448	Pembrolizumab	Ν		8.2.4		matastatic)				s/sheets V11 through 13
440	Fembroiizumab	IN	Immunomodulating	0.2.4		Melanoma (unresectable,				s/sheets v 11 through 13
449	Pembrolizumab	Ν		8.2.4		matastatic)				"
449	Fembroiizumab	IN	drugs	0.2.4						
450	Dirfonidono	Ν	Pulmonary Fibrosis	3.11	Individual	Idiopathic pulmonary fibrosis				
450	Pirfenidone	IN	Drugs affecting the	3.11	Individual	libiosis				
454	Dississation	N	5 5	0.4.7	Les alle d'als ser l					
451	Plerixafor	Ν	immune response	9.1.7	Individual	Stem cell mobilisation				
450	De se ell'ele se i de	Ν	5	8.2.4	Les alle d'als ser l	0				
452	Pomalidomide	N	drugs	8.2.4	Individual	Cancer				
450	De se ell'ele se i de	Ν	Immunomodulating	0.0.4	Les alle d'als ser l	Myelofibrosis and multiple				
453	Pomalidomide	N	drugs	8.2.4	Individual	myeloma				
						Chronic myelogenous				
			Destain Li			leukaemia (CML), Acute				
45.4	Devetivit		Protein kinase	0.4.5	La alla dalla - 1	lymphoblastic leukaemia				
454	Ponatinib	N		8.1.5	Individual	(ALL)				
			Multiple sclerosis							
455	Ponesimod	Ν	(MS)	10.2	Group	relapsing-remitting				2019
						Respiratory Distress				
456	Poractant alfa	Ν	Pulmonary surfactants	3.5.2	Individual	Syndrome				
						Licensed indications (Not				
						all blood products are				
			Blood-related products			listed in the BNF, but they				
457	Porcine Factor	N*	except Fibrin Sealants	none	Individual	are all excluded from PbR)				
401		IN	chooper ibilli dealdlits		mannada	For all invasive fungal	1		1	
						infections including those				
						associated with				Note that treatment of Allergic
						transplants and				
150	Posaconazole	Ν	Antifungolo	E 0 1	Individual					bronchopulmonary aspergillosis (ABPA) is CCG-commisisoned.
458 459	Posaconazole Pretomanid	N		5.2.1 5.1.9	Group	aspergillosis Tuberculosis				(ABPA) is CCG-commisisoned. Not in SPS
409	Fletomania	IN	Antibacterial Drugs	5.1.9	Group	Tuberculosis				NUL III 3P3

-			-							
			Intravenous/subcutane			Antibody deficiency				
			ous human normal			syndromes, Immunology,				
460	Privigen	N	immunoglobulins	14.5.1	Group	Neurology				
						Licensed indications (Not				
						all blood products are				
	_				_	listed in the BNF, but they				
461	Protein C	Ν	Blood related products	2.11	Group	are all excluded from PbR)				
						Licensed indications (Not				
						all blood products are				
						listed in the BNF, but they				
400	Drothrombin Complay	N		0.44	Crown	are all excluded from PbR)				
462	Prothrombin Complex	N	Blood related products	Z.11	Group					
			AIDS/HIV			HIV in combination with				
463	Raltegravir	Ν	antiretrovirals	5.3.1	Group	other anti-retroviral drugs				
						Wet age related macular				
						degeneration, diabetic				
						macular oedema, branch				
						and central retinal vein				
						occlusion, choroidal				
						neovascularisation				
			Subfoveal choroidal			secondary to pathological		NICE TA155 /	http://guidance.nice.org.uk/T	
464	Ranibizumab	С	neovascularisation	11.8.2	Individual	myopia	Monitored	274 / 283 / 298	Axxx etc	
404	Ranibizumab	C	neovascularisation	11.0.2	Individual	Пуоріа	Monitored	214/203/290	AXXX EIC	
						Treatment of acute				
			Gout and cytotoxic-			hyperuricaemia in patients				
			induced			with haematological				
465	Rasburicase	Ν	hyperuricaemia	10.1.4	Individual	malignancy				
405	Rasbullcase	IN	Protein kinase	10.1.4	Individual	manghancy				
466	Regorafenib	Ν	inhibitors	8.1.5	Individual	Cancer				
			Allergen			Allergic, eosinophilic				
467	Reslizumab	N	Immunotherapy	3.4.2	Individual	asthma				
-			Lysosomal Storage	-						
468	Reveglucosidase alfa	Ν	Disorder Drugs		Group	Pompe disease				2018
400		IN	Viral Hepatitis (B&C) &		Стобр	i ompe usease				2010
			respiratory Syncytial							
469	Ribavirin	Ν	Virus	5.3.5	Individual	Hepatitis C				
			Myelodysplastic			Myelodysplastic Syndrome				
470	Rigosertib	Ν	Syndrome	8	Individual	and pancreatic cancer				
-10		IN I	AIDS/HIV	Ŭ.	mannada	HIV in combination with	+	l	1	
474	Dila indala a			5.0.4	0					
471	Rilpivirine	Ν	antiretrovirals	5.3.1	Group	other anti-retroviral drugs				
							1			
			Torsion Dystonias and			Amyotropic lateral	1			
			other involuntary			sclerosis in motor neurone	1		http://guidance.nice.org.uk/T	
472	Riluzole	С	movements	4.9.3	Group	disease, neurology	Monitored	NICE TA20	A20	
		, v	Vasodilator		0.00p	allocabo, noticiogy			<u></u>	
	1					1				
			antihypertensive				1			
	1		drugs/Pulmanory			Pulmonary arterial				
473	Riociguat	Ν	Arterial Hypertension	2.5.1	Individual	hypertension				
			AIDS/HIV			HIV in combination with	1			
474	Ritonavir	Ν		5.3.1	Group	other anti-retroviral drugs				
474	Rituximab		Cytokine modulators			ANCA-positive vasculitis	+	l	1	
		N	/	10.1.3	Group				l	
476	Rituximab	Ν	Cytokine modulators	10.1.3	Group	Acquired haemophilia	ļ			
	1					Steroid sensitive nephrotic				
477	Rituximab	Ν	Cytokine modulators	10.1.3	Group	syndrime				
				-		Steroid resistant nephrotic				
478	Rituximab	Ν	Cytokine modulators	10.1.3	Group	syndrome	1			
4/0		IN		10.1.5	Group				l	
					1	Primary Sjorgen's				
479	Rituximab	Ν	Cytokine modulators	10.1.3	Group	Syndrome (PSS)				

480	Dituuimah	N	Outokino modulatoro	10.1.2	Crown	demyelinating				
480	Rituximab	IN	Cytokine modulators	10.1.3	Group	polyneuropathy				
						Connective tissue disease				
481	Rituximab	Ν	Cytokine modulators	10.1.3	Group	- interstital lung disease				
482	Rituximab	N	Cytokine modulators	10.1.3	Group	Graft versus host disease				
483	Rituximab	N	Cytokine modulators	10.1.3	Group	Myositis				
40.4	Dituuinaak	N	O tabia a madulatan	10.1.0	0	ABO-incompatible kidney				
484 485	Rituximab Rituximab	<u>N</u>	Cytokine modulators Cytokine modulators	10.1.3 10.1.3	Group Group	transplants Nephritis				
486	Rituximab	N N	Cytokine modulators	10.1.3	Group	Neuromyelitis Optica				
487	Rituximab	N	Cytokine modulators	10.1.3	Group	SLE				
						Immunoglobulin G4				
488	Rituximab	Ν	Cytokine modulators	10.1.3	Group	related disease				Added to match NHSE s/sheet
489	Rituximab	N	Cytokine modulators	10.1.3	Group	Neuromyelitis optica				Added to match NHSE s/sheet
490	Rituximab	N	Cytokine modulators	10.1.3	Group	Pemphigus Vulgaris				
491	Rituximab	N	Cytokine modulators	10.1.3	Group	Juvenile arthritis				
492	Rituximab	С	Cytokine modulators	10.1.3	Group	Refractory Primary Idiopathic Immune Cytopenias	Monitored		http://gmmmg.nhs.uk/docs/s ubgroups/sbgrp- hcdsg/GMMMG-Rituximab- recommendation-final.pdf	Unlicensed. Includes Refractory Idiopathic Thrombocytopenia Purpura (ITP), Autoimmune Haemolytic Anaemia (AIHA) and Evans syndrome.
493	Rituximab	С	Cytokine modulators	10.1.3	Group	Rheumatoid Arthritis, after failure of TNF inhibitor, Rheumatology	Monitored	NICE TA195	http://guidance.nice.org.uk/T A195 http://gmmmg.nhs.uk/docs/g uidance/GMMMG-RA- pathway-v4-1.pdf	
494	Rituximab (IV)	N	Cytokine modulators	10.1.3	Group	Cancer				
495	Rituximab subcutaneous formulation	N	Cytokine modulators	10.1.3	Group	Cancer				
496	Rituximab	C or N, seek guidance if necessary	Cytokine modulators	10.1.3	Group	All other indications	Individual funding			
497	Romiplostim	С	Platelet Disorder Drugs	9.1.4	Individual	Chronic immune thrombocytopenic purpura (ITP)	Monitored	NICE TA221	http://www.nice.org.uk/guida nce/TA221	While eltrombopag and romiplostim are the responsibility of CCGs regardless of the cause of the thromobcytopenia in adults, paediatrics are NHSE responsibility.
			Viral Hepatitis (B&C) &							
40.9	Popogintorferen elfe Ob	N	Respiratory Syncytial		Crown	Polycythemia vera; first-				2017
498	Ropeginterferon alfa-2b	N	Virus Drugs used in		Group	line			1	2017
499	Roxadustat	С	hypoplastic, haemolytic, and renal anaemias	9.1	Group	Anaemia in chronic kidney disease (non dialysis- dependent)	Individual funding			SPS says CCG commissioned. 2019
500	Roxadustat	Ν	Drugs used in hypoplastic, haemolytic, and renal anaemias	9.1	Group	Anaemia in chronic kidney disease (dialysis-induced)				SPS says CCG commissioned but use in dialysis-induced patients is confirmed by V11 to be NHSE. 2019
504	Durung liking its	N	Protein kinase	0.4.5	lan alle state on t	0				
501	Ruxolitinib	N	inhibitors	8.1.5	Individual	Cancer				
502	Sandoglobulin	Ν	Intravenous/subcutane ous human normal immunoglobulins	14.5.1	Group	Antibody deficiency syndromes, Immunology, Neurology				

	T	1	-	1				1		11
						Hyperphenylalaninaemia				
			Drugs used in			(HPA) [children with				
503	Sapropterin	N	Metabolic disorders	9.4.1	Individual	phenylketonuria]				
			_			Hyperphenylalaninaemia				
			Drugs used in			(HPA) [Maternal				
504	Sapropterin	N		9.4.1	Individual	phenylketonuria]				
			AIDS/HIV		_	HIV in combination with				
505	Saquinavir	N	antiretrovirals	5.3.1	Group	other anti-retroviral drugs				
									https://www.nice.org.uk/guid	
									ance/ta485	
									http://gmmmg.nhs.uk/docs/g	
									uidance/GMMMG-RA-	references to NICE and
506	Sarilumab	С	Cytokine modulators	10.1.3	Group		Monitored	NICE TA485	pathway-v4-1.pdf	GMMMG RA pathway updated
			Lysosomal Storage			Lysosomal acid lipase				
507	Sebelipase alfa	N	Disorder Drugs	9.8.1	Group	deficiency				
508	Secukinumab	N	Cytokine modulators	13.5.3	Group	Paediatric indications				
									https://www.nice.org.uk/guid	
									ance/ta350	
									http://gmmmg.nhs.uk/docs/g	
									uidance/GMMMG-Biologics-	
									pathway-for-psoriasis-v2-	reference to GMMMG psoriasis
509	Secukinumab	С	Cytokine modulators	13.5.3	Group	Psoriasis	Monitored	NICE TA350	0.pdf	pathway updated
	Ì				· · · · · · · · · · · · · · · · · · ·				https://www.nice.org.uk/guid	
									ance/ta445	
									http://gmmmg.nhs.uk/docs/g	references to NICE and
									uidance/GMMMG-AS-PsA-	GMMMG AS/ PsA pathway
510	Secukinumab	С	Cytokine modulators	10.1.3	Group	Psoriatic arthritis	Individual funding	NICE TA445	pathway-Final-v4.pdf	updated
0.0	Coodination		cytotatio includiatore		0.000		inamada ranang		https://www.nice.org.uk/guid	
									ance/ta407	
									http://gmmmg.nhs.uk/docs/g	
						Active Ankylosing			uidance/GMMMG-AS-PsA-	references to GMMMG AS/ PsA
511	Secukinumab	С	Cytokine modulators	10.1.3	Group	spondylitis	Monitored	NICE TA407	pathway-Final-v4.pdf	pathway updated
511	Secukinumab	U	Vasodilator	10.1.5	Group	spondyittis	wormored		patriway-r inai-v4.put	
			antihypertensive							
			drugs/Pulmonary			Pulmonary arterial				
510	Selexipag	Ν		2.5.1	Individual	hypertension				
512	Selexipag	IN	Artenai Hypertension	2.3.1	individual	hypertension				
										Drug still in development.
										Technology Appraisal currently
			I has a stand a second							
540	Q a ma la usia	0	Hypertension and		ha allo dale sa l	Acute decompensated	In the state of the second second			suspended indefinitely by NICE.
513	Serelaxin	С	heart failure		Individual	heart failure	Individual funding			2018
			Viral Hepatitis (B&C) &							
544	O a trach un sin		Respiratory Syncytial	5 0 0	0	Lise stills				
514	Setrobuvir	N	Virus	5.3.3	Group	Hepatitis C				
										Only PbR ecluded when used for
			Drugs used in							a metabolic disorder. Not in
515	Sialic acid	N	Metabolic disorders	9.8.1	Individual	Myopathy				SPS.
			Vasodilator							
			antihypertensive							
L.	Sildenafil (only when		drugs/Pulmonary		I	Pulmonary arterial				
516	used for PAH)	N		2.5.1	Individual	hypertension				
517	Siltuximab	N*	Cytokine modulators	8.2.4	Group	Castleman's Disease				
			Viral Hepatitis (B&C) &							
			respiratory Syncytial							
518	Simeprevir	Ν	Virus	5.3.3	Group	Hepatitis C				
			Viral Hepatitis (B&C) &							
	Simeprevir /		respiratory Syncytial							
519	peginterferon + ribavirin	Ν		5.3.3	Group	Hepatitis C				Added to match NHSE s/sheet
		1					1			

	Sirukumab	N*	Drugs affecting the immune response	10.1.3	Individual	Giant cell (temporal) arteritis			+	IL-6 inhibitor. 2019 IL-6 inhibitor. Possibly Q3 2017. Not on NICE's agenda.
		N	immune response	10.1.3	Individual	anenus				IL-6 inhibitor. Possibly Q3 2017.
<u>521 S</u>	Sindumob									
<u>521 S</u>	Sirukumah									Not on NICE's agenda.
<u>521 S</u>	Sindumoh			1						
<u>521 S</u>	Sirukumoh			1						NHSE states on V11 that it will
<u>521 S</u>	Sirukumah		1	i i						be responsible for paediatric
521 S	Sirukumoh			i i						indications should a positive
521 S	Sirukumoh		Drugs affecting the	i			Individual			NICE TA become available for
	Sirukumab	С	immune response	10.1.3	Individual	Rheumatoid arthritis	Funding			adult indications.
										New addition to Annex A 2016
										/17. Only PbRe when used in
										metabolic disorders. Not in
'										proposed list for 2017/19 so
										removed
. /										N.B. This drug is not in Annex A
. /			Drugs used in							but is included here to match
522 <mark>S</mark>	Sodium benzoate	<mark>N*</mark>	Metabolic disorders		Individual					NHSE s/sheet V11
	Social Delizeate		Hypnotics and		Individual	Narcolepsy - paediatric				
523 S	Sodium oxybate	Ν		4.1.1	Individual	services only				1
020 0	eedium exybate				individual			·	http://gmmmg.nhs.uk/docs/n	
				1					ts/NTS%20Sodium%20Oxvb	All requests to go to CCGs for
			Hypnotics and	i					ate%20for%20narcolepsy.p	detailed consideration at IFR
524 S	Sodium oxybate	С		4.1.1	Individual	Narcolepsy with cataplexy	Individual funding	GMMMG NTS	df	Panels
524 5	Socium oxybate	C	Drugs used in	4.1.1	Inulvidual		inulvidual funding			r dileis
525 S	Sodium phenylbutyrate	Ν		9.8.1	Individual	Urea cycle disorders				1
525 3	Sodium prienyibutyrate	IN	Viral Hepatitis (B&C) &		Individual					l
	Cofoshuuir / doolotoouir u			i						Entring new metab NUICE of
	Sofosbuvir / daclatasvir +	N	respiratory Syncytial	5 0 0 0	0	Lisa stitis O				Entries now match NHSE s/
526 ri	ribavirin	N		5.3.3.2	Group	Hepatitis C		<u> </u>	_ /	sheet
			Viral Hepatitis (B&C) &	i						
	Sofosbuvir / ledipasvir +/-		respiratory Syncytial		0					Entries now match NHSE s/
527 ri	ribavirin	N		5.3.3.2	Group	Hepatitis C				sheet
			Viral Hepatitis (B&C) &	i						
	Sofosbuvir /		respiratory Syncytial							Entries now match NHSE s/
528 p	peginterferon + ribavirin	N		5.3.3.2	Group	Hepatitis C				sheet
. /			Viral Hepatitis (B&C) &	i						
			respiratory Syncytial							Entries now match NHSE s/
529 <mark>S</mark>	Sofosbuvir / velpatasvir	N		5.3.3.3	Group	Hepatitis C				sheet
		_	Drugs affecting the				Individual			1
530 <mark>S</mark>	Solanezumab	С		4.11	Individual	Alzheimer's disease	Funding			2020
			Growth Hormone &	i						1
			growth hormone	i		Growth hormone			http://www.nice.org.uk/guida	1
531 S	Somatropin	С		6.5.1	Individual	deficiency children	Monitored	NICE TA188	<u>nce/TA188</u>	<u> </u>
			Growth Hormone &	1						1
			growth hormone	1		Severe growth hormone			http://www.nice.org.uk/guida	1
532 S	Somatropin	С		6.5.1	Individual	deficiency in adults	Monitored	NICE TA64	nce/TA64	
			Protein kinase	1					1	1
533 S	Sorafenib	N		8.1.5	Individual	Cancer	1			<u> </u>
			AIDS/HIV	1		HIV in combination with			1	1
534 S	Stavudine	N		5.3.1	Group	other anti-retroviral drugs				l
			Intravenous/subcutane	1		Antibody deficiency			1	1
			ous human normal	1		syndromes, Immunology,			1	1
535 S	Subcuvia	N		14.5.1	Group	Neurology		L		l
Γ			Intravenous/subcutane	1		Antibody deficiency				l
			ous human normal	1		syndromes, Immunology,				1
536 S	Subgam	Ν	immunoglobulins	14.5.1	Group	Neurology				1
				1						
•			1	1					1	End stage renal disease.
1			1 1							
										V11 through 13 place this at the
			Phosphate biniding							

			Drotain kinaaa	1				1		
538	Sunitinib	Ν	Protein kinase inhibitors	8.1.5	Individual	Cancer				
238	Suniunib	IN	Innibilors	8.1.5	Individual	Cancer				
			Pland related products							
500		N	Blood-related products except Fibrin Sealants		0	Lisses and the A				
539	Susoctocog alfa	N		9.1.3	Group	Haemophilia A				
			Vasodilator							
			antihypertensive							
	Tadalafil (only when used		drugs/Pulmonary			Pulmonary arterial				
540	for PAH)	N	Arterial Hypertension	7.4.5	Individual	hypertension				
										Despite PSS 46 saying CCGs
										commission the majority of
										treatment services for patients
										with amyloidosis, NHSE V13
										now lists this and so the
										commissioner has been
										changed to NHSE.
										The two indications rows 541
										and 542 will be merged on the
	Tafamidis		Neurodegenerative			Amyloidosis; senile,				next version.
541	Vyndagel	N	Conditions	4.9.3	Individual	systemic	Individual funding			2022
341	Vynuager	IN	Conditions	4.9.5	Inuiviuuai	systemic	individual funding		-	2022
						Cardiovascular disorders;				
	Tafaasidia		National and a second sections							
- 10	Tafamidis		Neurodegenerative			transthyretin				
542	Vyndaqel	N	Conditions		Individual	cardiomyopathy (TTR-CM)				NHSE commissioned on V13
			Lysosomal Storage		-					
543	Taliglucerase alfa	N	Disorder Drugs		Group	Gaucher's disease				
544	Tanezumab	С	Cytokine modulators	4.7	Group	Osteoarthritis	Individual funding			2018
			Viral Hepatitis (B&C) &							
			respiratory Syncytial							
545	Taribavirin	Ν	Virus	5.3.5	Group	Hepatitis C				
			Cytokine modulators							
546	Teduglutide	N	[GLP-2 analogue]	1	Group	Short bowel syndrome				
			Viral Hepatitis (B&C) &							
			respiratory Syncytial							
547	Telaprevir	Ν		5.3.3	Group	Hepatitis C				
• • •			Viral Hepatitis (B&C) &							
			respiratory Syncytial							
548	Telbivudine	Ν	Virus	5.3.3	Group	Hepatitis B				
040		in in	Protein kinase	0.0.0	Cloup					
549	Temsirolimus	Ν	inhibitors	8.1.5	Individual	Cancer				
549	Temsiloiimus	IN	AIDS/HIV	0.1.5	Individual	HIV (or Hepatitis with				
550	Topofovir	N I		E 2 1	Crown					
550	Tenofovir Tenofovir with	N	antiretrovirals AIDS/HIV	5.3.1	Group	some drugs)				
FF4	Tenofovir with			5.0.4	0	HIV (or Hepatitis with				
551	Emtricitabine	N	antiretrovirals	5.3.1	Group	some drugs)				
	Tenofovir with									
	Emtricitabine and		AIDS/HIV			HIV (or Hepatitis with				
552	Efavirenz	Ν	antiretrovirals	5.3.1	Group	some drugs)				
										Further entries of combination
										products required to match
	Tenofovir with									NHSE s/ sheet but all prodducts
	emtricitabine and		AIDS/HIV			HIV (or Hepatitis with				containing tenofovor are
553	rilpivrine	Ν	antiretrovirals	5.3.1	Group	some drugs)				commissioned by NHSE
<u> </u>			Immunomodulating							
554	Teriflunomide	Ν	drugs	8.2.4	Individual	multiple sclerosis				
						Osteoporosis in men and				
			Drugs affecting bone			iuveniles				
555	Teriparatide	Ν	metabolism	6.6.1	Individual	Osteogenesis imperfecta	Individual funding			
			Drugs affecting bone						http://guidance.nice.org.uk/T	
556	Teriparatide	С	metabolism	6.6.1	Individual	Osteoporosis in women	Monitored	NICE TA161	A161	
555	ronpulation	0	metabolisiti	0.0.1	mannaudi	Colooporosis in women	monitoreu		<u></u>	1

			Growth Hormone &							
			growth hormone			HIV-associated				
557	Tesamorelin	?	0	13.1	Individual	lipodystrophy				SPS says filing withdrawn.
557	Tesamorelin	<i>!</i>	Drugs used in	13.1	Individual	Hyperphenylalaninaemia				SPS says hing withdrawn.
550	Totrobudrobiontorio	N		0.4.4	المعانية فاسما	(HPA)				
558	Tetrahydrobiopterin	N	Metabolic disorders	9.4.1	Individual	(ПРА)				national list says "for non-Cystic
										Fibrosis indications" yet only in
										SPS in combiantion with
										ivacaftor for CF. Category
559	Tezacaftor	N		3.7	Group	Cystic Fibrosis				changed to NHSE as on V11.
500	The all all area into	N	Immunomodulating	0.0.4	la alla dale an l	0				
560	Thalidomide	N	drugs	8.2.4	Individual	Cancer				
						Licensed indications (Not				
						all blood products are				
			Blood-related products		_	listed in the BNF, but they				
561	Thrombin	N	except Fibrin Sealants	none	Group	are all excluded from PbR)				
	Thrombomodulin,						Individual			
562	Recombinant Human	С	Fibrinolytics	2.10.2	Individual	Septic shock (Sepsis)	Funding			2017
							Individual			IL-23 inhibitor, unlikely before
563	Tildrakizumab	С	Skin Conditions	13.5	Individual	Psoriasis	Funding			2020
			AIDS/HIV			HIV (or Hepatitis with				
564	Tipranavir	N	antiretrovirals	5.3.1	Individual	some drugs)				
						Management of cystic				
565	Tobramycin	N	Antibacterial Drugs	5.1.4	Individual	fibrosis				
										For children transitioning to adult
										services and becoming a CCG
									http://ammma.nhs.uk/docs/s	commissioning responsibility,
										category is monitored when in
						Paediatric indications				line with the referenced GMMMG
566	Tocilizumab IV	Ν	Cvtokine modulators	10.1.3	Group	(where adult TA available)			amended-post-meeting.pdf	quidance.
567	Tocilizumab IV	N	Cytokine modulators	10.1.3	Group	Juvenile arthritis			amended post meeting.pdi	guidance.
307		IN	Cytokine modulators	10.1.5	Group	Giant Cell arteritis				
568	Tocilizumab IV	N	Cytokine modulators	10.1.3	Group	Takayasu arteritis				
300		IN	Cytokine modulators	10.1.3	Group	Takayasu artentis			http://www.nice.org.uk/guida	
									nce/ta375	
									Tice/las/s	
									http://gmmmg.nhs.uk/docs/g	
								NICE TA375 / GM	uidance/GMMMG%20RA%2	
500		0		10.1.0	<u> </u>			Harmonised	0Pathway%2022%20april_2	
569	Tocilizumab	С	Cytokine modulators	10.1.3	Group	Rheumatoid arthritis	Monitored	biologics pathway	015.pdf	
570	Tofacitinib	N	Cytokine modulators		Group	Any paediatric use				
								https://www.nice.		
1								org.uk/guidance/t		
1								a480		
								http://gmmmg.nh		
								s.uk/docs/guidan		
								ce/GMMMG-RA-		reference to NICE and GMMMG
571	Tofacitinib	С	Cytokine modulators	10.1.3	Group	Rheumatoid Arthritis	Monitored	pathway-v4-1.pdf	ance/ta480	RA pathway updated
						Psoriatic arthritis,				These are potential future
572	Tofacitinib	С	Cytokine modulators	10.1.3, 1.5.4	Group	ulcerative colitis	Individual funding			indications
							Ŭ			
1										NHS England has stated that it
1										is the responsible commissioner
1	Tolvaptan		Vasopressin V2							for this drug only when used in
573	Samsca	N		6.5.2	Individual	Hyponatraemia in cancer				this indication.
5.5						Hyponatraemia and other				
1	Tolvaptan		Vasopressin V2			endocrine uses including				
574	Samsca	с		6.5.2	Individual	SIADH	Individual funding			
574	Carrista			0.0.2	mumuual		individual futfullity			

					1			1		
	Tolvaptan		Vasopressin V2			Autosomal dominant			http://www.nice.org.uk/guida	New row inserted for this
575	Jinarc	С	receptor antagonist	6.5.2	Individual	polycystic kidney disease	Monitored	NICE TA358	nce/ta358	indication. CCG commissioned
0.0		Ű,	receptor antagemet	01012	individual		literitered			
			Allergen							SPS says CCG-commissioned
576	Tralokinumab	N	Immunotherapy	3.4	Group	Asthma - severe				but on NHSE V11.
			Blood-related products		-					
577	Trenonacog alpha	N	except Fibrin Sealants	2.11	Group	Haemophilia B				
			Vasodilator							
	Treprostinil		antihypertensive drugs/Pulmanory			Pulmonary arterial				
578	diethanolamine	N	Arterial Hypertension	2.5.1	Individual	hypertension				
570	dictitationalinite		Vasodilator	2.0.1	individual	hypertension				
			antihypertensive							
			drugs/Pulmanory			Pulmonary arterial				
579	Treprostinil sodium	N	Arterial Hypertension	2.5.1	Individual	hypertension				
										Not a new drug. No licensed
			Drugs used in							preparation available in UK;
580	Trientine	N	Metabolic disorders		Individual	Wilson's Disease				imported.
						Licensed indications (Not				introvenesse formulation of
						all blood products are listed in the BNF, but they				intravenous formulation of recombinant factor VIII (octocog
581	Turoctocog alfa	N	Blood related products	2 11	Group	are all excluded from PbR)				alfa, rFVIII)
301		IN	biood related products	2.11	Group					
										SPS suggests this use is NHSE-
										commissioned. Also used for
										hereditary orotic aciduria, an
						Fluorouracil (5-FU)				ultra-rare metabolic disorder.
582	Uridine triacetate	N*	Poisoning	9.8.1	Individual	overexposure or toxicity				2019
			Drugs affecting the			Paediatric indications				
583	Ustekinumab	N	immune response	10.3 / 13.5	Individual	(where adult TA available)				
									http://guidance.nice.org.uk/T A180	
									A 180	
									GMMMG guidance for	
									sequential use:	
									http://gmmmg.nhs.uk/docs/g	
									uidance/GMMMG-Biologics-	
			Drugs affecting the						pathway-for-psoriasis-v2-	reference to GMMMG pathway
584	Ustekinumab	С	immune response	13.5	Individual	Psoriasis (plaque)	Monitored	NICE TA180	0.pdf	updated
									http://www.nice.org.uk/guida	
									<u>nce/ta340</u>	
									http://ammma.sha.uk/da.sa/s	
									http://gmmmg.nhs.uk/docs/g uidance/GMMMG%20AS%2	
			Drugs affecting the						0PsA%20pathway%20v4%2	
585	Ustekinumab	с	immune response	10.3	Individual	Psoriatic arthritis	Monitored	NICE TA340	0FINAL.pdf	
		Ŭ Ŭ			marriada					
									https://www.nice.org.uk/guid	
									ance/ta456	
									http://gmmmg.nhs.uk/docs/g	
									uidance/Biologics-pathway-	
			Drugs affecting the						for-Inflammatory-Bowel-	reference to NICE and GMMMG
586	Ustekinumab	С	immune response	1.5	Individual	Crohn's Disease	Monitored	NICE TA456	Disease-in-Adults-v2-0.pdf	pathway updated
		_	Drugs affecting the	10.0						
587	Ustekinumab	С	immune response	10.3	Individual	Any other use	Individual funding			

			Drugs used in							Trials found for use in dialysis-
			hypoplastic,			Anaemia in chronic kidney	,			dependent patients (NHSE) and
			haemolytic, and renal			disease (non dialysis-				non-dialysis-dependent patients
588	Vadadustat	С	anaemias	9.1	Group	dependent)	Individual funding			(CCG)
			Drugs used in		-		Ŭ			Trials found for use in dialysis-
			hypoplastic,			Anaemia in chronic kidney	,			dependent patients (NHSE) and
			haemolytic, and renal			disease (dialysis-				non-dialysis-dependent patients
589	Vadadustat	N	anaemias	9.1	Group	dependent)				(CCG)
			Cytomegalovirus			CMV retinitis / Prophylaxis				
590	Valganciclovir	N	infection	5.3.2.2	Individual	CMV +ve donor transplant				
										Unique delivery system only
										(thermosensitive mPEG- PLCPPA hydrogel?)
591	Vancomycin	C?	Antibacterial Drugs	5.1.7	Individual					Not in SPS
291	Vancontych	U?	Protein kinase	5.1.7	muniuuai					NOT IN SF 3
592	Vandetanib	N	inhibitors	8.1.5	Individual	Thyroid cancer				
002			Growth Hormone &	01110	Individual					
			growth hormone			Somatostatin analogue for	Individual			
593	Vapreotide	С	Receptor Antagonist		Individual	Oesophageal varices	Funding			
			Drugs affecting the			Paediatric indications				
594	Vedolizumab	N	immune response	1.5.3	Individual	(where adult TA available)				
			Drugs affecting the						http://www.nice.org.uk/guida	
595	Vedolizumab	С	immune response	1.5.3	Individual	Crohn's Disease	Monitored	NICE TA352	nce/ta352	
		_	Drugs affecting the						http://www.nice.org.uk/guida	
596	Vedolizumab	С	immune response	1.5.3	Individual	Ulcerative colitis	Monitored	NICE TA342	<u>nce/ta342</u>	
507		N	Lysosomal Storage	9.8.1	0					
597	Velaglucerase alfa	N	Disorder Drugs Drugs affecting bone	9.8.1	Group	Gaucher's disease				
598	Velcalcetide	Ν	metabolism	6.5	Individual	Hyperparathyroidism				
530	Velcalcellue	in in	Protein kinase	0.5	Individual					
599	Vemurafenib	N	inhibitors	8.1.5	Individual	Melanoma				
						Wet age related macular				
						degeneration (with				
						predominantly classic				
						subfoveal chroidal				
			Subfoveal choroidal			neovascularisation			http://guidance.nice.org.uk/T	
600	Verteporfin	С	neovascularisation	11.8.2	Individual	(CNV)), opthalmology	Monitored	NICE TA68	<u>A68</u>	
			Intravenous/subcutane			Antibody deficiency				
c01	Vizer	N	ous human normal	14.5.1	Craun	syndromes, Immunology,				
601	Vigam	N	immunoglobulins Intravenous/subcutane		Group	Neurology Antibody deficiency				
			ous human normal			syndromes, Immunology,				
602	Vivaglobin	Ν	immunoglobulins	14.5.1	Group	Neurology				
002	Vivagiobili		Intranoglobalina	14.0.1	Cioup	Neurology				
						Licensed indications (Not				
						all blood products are				
	Von Willebrand factor,					listed in the BNF, but they				
603	recombinant	N	Blood related products	2.11	Group	are all excluded from PbR)			
						For all invasive fungal				
						infections including those				Note that treatment of Allergic
004				5.0.4		associated with				bronchopulmonary aspergillosis
604	Voriconazole	N	Antifungals	5.2.1	Individual	transplants		+		(ABPA) is CCG-commisisoned.
605	Voriconazole	Ν	Antifungele	5.2.1	Individual	Chronic pulmonary				
005	VUICUIIAZUIE	IN	Antifungals	J.Z. I	muiviuuai	aspergillosis	1			1

								I think the National list is mixed up: winfuran would have been for treatment of severe uraemic pruritus in patients with end- stage kidney disease on dialysis but the EMA refused a MA on 19/12/13.
								KP-1461 is an anti HIV drug, the
			AIDS/HIV					development status of which is
606	Winfuran (KP 1461)	N*	antiretrovirals		Individual			currently unclear.
607	Ziconotide	Ν	Non-opioid analgesics	4.7.1	Individual	Severe, chronic pain		
			AIDS/HIV			HIV (or Hepatitis with		
608	Zidovudine	Ν	antiretrovirals	5.3.1	Group	some drugs)		
	Zidovudine with		AIDS/HIV			HIV (or Hepatitis with		
609	Lamivudine	N	antiretrovirals	5.3.1	Group	some drugs)		
	Zidovudine with		AIDS/HIV			HIV (or Hepatitis with		
610	Lamivudine and Abacavir	Ν	antiretrovirals	5.3.1	Group	some drugs)		

NOLE. NITOL HAS DEEN UK	ear that existing GP [=0	Job prescribing of thes	e should NOT be	repainaled to NHSI	E. This section is similar to N	vhoe s urug list iriu	ICALIONS IOF INTO ET	igianu urugs list v 13 23/03/20	J18
	Commissioner								
	Category								
	CDF = Cancer drugs								
	fund - check with								
	latest version of					Prior Approval	Commissioning	Commissioning Policy	
o. Drug Name	NHSE list	PBR Category	BNF category	Group	Indication	Category	Policy Type	Link	Comments
		Lambert Eaton							
3,4 Diaminopyridine	Ν	Myasthenic Syndrome							
Aflibercept	N	Cancer			Cancer				
· ····· · · · · · · · · · · · · · · ·					Treatment of breast				
					cancer patients with				
					documented taxane				
Albumin bound paclitaxel	Ν	Cancer			hypersensitivity				
Atezolizumab	CDF	Cancer			Cancer				new to accord with NHSE V13
Autologous Chondrocyte									
implantation	N				Articular cartilage defect				new to accord with NHSE V13
							New patients only		
					- · ·		until formal		
		l			Transplant		repatriation		
Azathioprine	N	Immunosuppressants			immunosuppression only		agreed		
Bendamustine	N / CDF	Cancer			Cancer				
Blinatumomab	N	Cancer			Cancer				new to accord with NHSE V13
Brentuximab		Cancer			Cancer				
Cabazitaxel	N N / CDF	Cancer			Cancer				
Cabozantinib		Cancer			Cancer				
Carfilzomib	N	Cancer			Cancer				new to accord with NHSE V13 Consult NHSE guidance /
Chamatharany		Canaar			Canaar				
Chemotherapy	N / CDF	Cancer			Cancer		New patients only		spreadsheet for individual drugs
							until formal		
					Trananlant				
Cieleanaria	N				Transplant		repatriation		
Ciclosporin	IN	Immunosuppressants			immunosuppression only	1	agreed	1	

		Hypercalcaemia and	Hyperparathyroidism -		only as per NICE TA117 [i.e. dialysis patients]; otherwise is i Tariff. See Specialist Services
Cinacalcet	Ν	hypercalciuria	dialysis patients only		Manual.
Clofarabine	CDF	Cancer	Cancer		
		Drugs for mineral bone			
Colestilan	Ν	disorders	Adult renal dialysis only		
Daratumumab	CDF		Cancer		new to accord with NHSE V13
Darbepoetin	N N	Erythropoetins	Dialysis-induced anaemia		only as per NICE CG 114
Epoetin (all variants)	N	Erythropoetins	Dialysis-induced anaemia		only as per NICE CG 114
Eribulin	N / CDF	Cancer	Cancer		
Enbaint	N/CDI	Drugs for mineral bone	Hyperparathyroidism -		
Etelcalcetide	Ν	disorders	dialysis patients only		new to accord with NHSE V13
	IN				Thew to accord with NHSE V13
Factor X (Cogadex)	N	Blood related products	Hereditary Factor X deficiency		new to accord with NHSE V12
		Protein kinase			
Ibrutinib	N / CDF	inhibitors	Cancer		
		Protein kinase			
Idelalisib	N	inhibitors	Cancer		
Ipilimumab	N	Cancer	Cancer		
		Phosphate binding			
Lanthanum	Ν	agents	Adult renal dialysis only		
		Protein kinase			
Lenvatinib	N	inhibitors			
Mesenchymal stem cells			Acute GvHD and other		
(e.g. Prochymal®)	Ν		indications (BCSH)		
	IN		Indications (BCSII)	New patients only	
				until formal	
			Transmissio		
			Transplant	repatriation	
Mycophenolate mofetil	N	Immunosuppressants	immunosuppression only	agreed	
				New patients only until formal	
			Transplant	repatriation	
Mycophenolic acid	Ν	Immunosuppressants	immunosuppression only	agreed	
Nelarabine	CDF	Cancer	Cancer		
Nivolumab	N/CDF	Cancer	Cancer		
Obinutuzumab	N / CDF	Cancer	Cancer		
Olaparib	N	Cancer	Cancer		
Olartumumab	CDF	Cancer	Cancer		
Osimertinib	CDF	Cancer	Cancer		
Palbociclib	N	Cancer	Cancer		
Panitumumab	N	Cancer	Cancer		
Panobinostat	N	Cancer	Cancer		
	N	Cancer	Cancer		
Pegaspargase	IN	Gancer	Cancer		
Pegylated liposomal		Conner	Conser		
doxorubicin	N / CDF	Cancer	Cancer	 	
Pemetrexed	N / CDF	Cancer	Cancer		
Peptide receptor					
radionucleotide therapy	CDF	Cancer	Cancer		
Pertuzumab	N	Cancer	Cancer		
Pixantrone	N	Cancer	Cancer		
Pomalidomide	CDF	Cancer	Cancer		
Ponatinib	N*	Cancer	Cancer		
Protein kinase inhibitors	Ν		Endocrinology; non- malignant conditions		
Radium-223 dichloride	N / CDF	Cancer	Cancer		
Radium-223 dichionde	N N	Cancer	Cancer		
Ribociclib	N	Cancer Disadia a	Cancer		
Sevelamer	Ν	Phosphate binding agents	Adult renal dialysis only		

			Transplant	New patients only until formal repatriation	
Sirolimus	N	Immunosuppressants	immunosuppression only	agreed	
Strimvelis	N	ATMP	Adenosine deaminase deficiency - severe combined immunodifieicency		
Tacrolimus	N	Immunosuppressants	Transplant immunosuppression only	New patients only until formal repatriation agreed	
Talimogene laherparepvec	N	Cancer	Cancer		
Temozolomide	Ν	Cancer	Endocrinology; non- malignant conditions		
Tivozanib	CDF	Cancer	Cancer		
Trabectedin	N	Antineoplastic drugs	Cancer		
Trastuzumab	N	Cancer	Cancer		
Trastuzumab emtansine	N	Cancer	Cancer		
Trifluridine + tipiracil	N	Cancer	Cancer		
Venetoclax	CDF	Cancer	Cancer		

Notes:

• Treatment of severe manifestations of some diseases is NCB commissioned e.g. Severe and / or fistulating Crohn's. Lanreotide / octreotide are CCG commissioned for non-cancer uses

• CCGs commission for all patients with autoimmune rheumatic diseases or rare arthropathies where the diagnosis is already established and the manifestations are well-controlled by conventional management and the patient and the rheumatologist are satisfied with treatment response and progress of the disease.

• Recommendations for cancer chemotherapy are to be excluded from 1/4/13. However, non-chemotherapy indications for the following will be CCG commissioned *if* use relates to a non-NHSE service: cladribine, lenalidomide, thalidomide, rilonacept, azacitidine, bevacizumab, bortezomib, cetuximab, protein kinase inhibitors, alemtuzumab.

Drugs for which NHS England is the Commissioner are not necessarily routinely commissioned.

Many drugs for which NHS England is the Commissioner are only commissioned by NHSE when from Specialist Centres; funding for requests outside of specialist centres would fall to CCGs.

For information: [reference A Strategic Framework for Intestinal Failure and Home Parenteral Nutrition Services for Adults in England. National Commissioning Group for Highly Specialised Services April 2008]

Type I – this type of Intestinal Failure is short-term, self limiting and often peri-operative in nature. Type I Intestinal Failure is common and these patients are managed successfully in a multitude of healthcare settings, especially surgical wards, including all units which perform major, particularly abdominal surgery. Some patients on high dependency units (HDU) and intensive care units (ICU) will also fall into this category.

Type II – Type II IF occurs in metabolically unstable patients in hospital and requires prolonged parenteral nutrition over periods of weeks or months. It is often associated with sepsis, and may be associated with renal impairment. These patients often need the facilities of an Intensive Care or High Dependency Unit for some or much of their stay in hospital. This type of IF is rarer and needs to be managed by a multi-professional specialist intestinal failure team. Effective management of Type II IF can reduce the likelihood of the development of Type III Intestinal Failure.

Type III – Type III is a chronic condition requiring long term parenteral feeding. The patient is characteristically metabolically stable but cannot maintain his or her nutrition adequately by absorbing food or nutrients via the intestinal tract. These are, in the main, the group of patients for which Home Parenteral Nutrition (HPN) is indicated.